

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 501/24, A61K 31/545		A1	(11) International Publication Number: WO 96/35692
			(43) International Publication Date: 14 November 1996 (14.11.96)
(21) International Application Number: PCT/EP96/02023 (22) International Filing Date: 10 May 1996 (10.05.96) (30) Priority Data: A 794/95 11 May 1995 (11.05.95) AT A 992/95 12 June 1995 (12.06.95) AT A 698/96 17 April 1996 (17.04.96) AT A 733/96 23 April 1996 (23.04.96) AT		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): BIOCHEMIE GESELLSCHAFT MBH [AT/AT]; A-6250 Kundl (AT). (72) Inventors; and (75) Inventors/Applicants (for US only): ASCHER, Gerd [AT/AT]; Daxerfeld 3, A-6250 Kundl (AT). LUDESCHER, Johannes [AT/AT]; Kleinsöell 101, A-6252 Breitenbach (AT). (74) Agents: WYMAN, Gerard et al.; Sandoz Technology Ltd., Patents & Trademarks Division, CH-4002 Basel (CH).			
(54) Title: ANTIBACTERIAL CEPHALOSPORINS			
(57) Abstract			
A compound of formula (I) wherein Ac, R ₁ and R ₂ have various meanings, a process for a preparation thereof and its use as a pharmaceutical, i.e. as antibacterial agent.			

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LT	Lithuania	SN	Senegal
CN	China	LU	Luxembourg	SZ	Swaziland
CS	Czechoslovakia	LV	Latvia	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MD	Republic of Moldova	TJ	Tajikistan
DK	Denmark	MG	Madagascar	TT	Trinidad and Tobago
EE	Estonia	ML	Mali	UA	Ukraine
ES	Spain	MN	Mongolia	UG	Uganda
FI	Finland	MR	Mauritania	US	United States of America
FR	France			UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Antibacterial Cephalosporins

The present invention relates to antibacterial compounds which are 7-acylamino-3-(imino)methyl cephalosporins.


Particularly the present invention provides a compound of formula




wherein

R_1 denotes hydrogen or an ester moiety,

R_2 denotes a group of formula




IIa



IIb

or




IIc

wherein


Y denotes hydrogen, alkyl, alkenyl, acyl, carbamoyl or aryl

R_4 denotes hydrogen, alkyl, alkenyl, cycloalkyl, aryl, acyl or heterocyclyl

R_5 denotes hydrogen, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, or a group of formula




IIId



IIe

or



IIIf

wherein

R_7 denotes alkyl or aryl

R_8 denotes hydrogen, cycloalkyl or alkyl

R_9 denotes hydrogen or alkyl

R_{10} denotes hydrogen, alkyl, hydroxy, amino, phenyl, alkenyl, cycloalkyl, aryl, heterocyclyl or a group of formula



wherein Phe denotes aryl

R_9 and R_{10} together with the nitrogen atom denote heterocyclyl,

Z denotes oxygen, sulphur or $N-R_{13}$, wherein

R_{13} denotes hydrogen, alkyl or cycloalkyl


R_{11} denotes hydrogen, alkyl, aryl, cycloalkyl or heterocyclyl, or

R_4 and R_5 together with the nitrogen atom denote heterocyclyl,


R_6 denotes heterocyclyl, and

Ac denotes

(i) a group



(ii) a group of formula



wherein

B denotes N or CH

Z₁ denotes aryl, cycloalkyl, 1,4-cyclohexadienyl or heterocyclyl

Z₂ denotes hydrogen, alkyl or -CH₂COOZ₃, wherein

Z₃ denotes hydrogen, alkyl or cycloalkyl

Z₃ denotes hydrogen or alkyl

Z₄ denotes hydrogen or an organic radical

D denotes oxygen or CH₂.

A subgroup of the invention comprises any of the individual groups of significances mentioned therein.

R₁ may be hydrogen or an ester moiety. An ester moiety includes alkyl, preferably C₁₋₆alkyl; arylalkyl, for example benzyl, alkoxybenzyl, such as 4-methoxybenzyl; indanyl, phthalidyl, alkoxymethyl, *e.g.* methoxymethyl; (C₁₋₆)alkanoyloxy(C₁₋₆)alkyl, (C₁₋₆)alkoxy-carbonyl-oxy(C₁₋₆)alkyl, glycyloxymethyl, phenylglycyloxymethyl, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl and ester moieties which form with the COO- group a physiologically hydrolysable and acceptable ester, *e.g.* such known to be hydrolysable ester groups in the field of cephalosporins. A compound of formula I may thus be in the form of an physiologically-hydrolysable and -acceptable ester. By physiologically-hydrolysable and -acceptable esters as used herein is meant an ester in which the COO-group is esterified and which is hydrolysable under physiological conditions to yield an acid which is itself physiologically tolerable at dosages to be administered. The term is thus to be understood as defining regular pro-drug forms. An ester moiety may be preferably a group which is easily hydrolysable under physiological conditions. Such esters may be administered preferably orally. Parenteral administration may be indicated if the ester *per se* is an active compound or, if hydrolysis occurs in the blood.

Y may be preferably hydrogen, unsubstituted alkyl or alkyl substituted by *e.g.* hydroxy or, preferably the residue of a carboxylic acid. The residue of a carboxylic acid includes the residue of a carboxylic acid in free form or in salt form, of a carboxylic acid ester and of a carboxylic acid amide. The carboxylic acid is, for example, a C₁₋₇ carboxylic acid, preferably a C₁₋₅ aliphatic carboxylic acid, an alkyl part thereof including lower alkyl. The alkoxy group of a carboxylic acid ester includes C₁₋₆, preferably C₁₋₄alkoxy. Alkyl is preferably lower alkyl. The alkyl group is preferably unsubstituted or substituted by

carboxylic acid residues.

R₄ may be preferably hydrogen or alkyl, for example lower alkyl.

R₅ may be preferably hydrogen; unsubstituted alkyl; alkyl substituted for example by oxo, alkyl or halogenated alkyl; amino; one or several fold substituted heterocyclyl; or a group of formulae IId, IIe, II f. Heterocyclyl includes unsaturated or saturated heterocyclyl having, e.g. 5 or 6 ring members and, for example, 1 to 3 hetero atoms, such as N, O, S, preferably N, or condensed heterocyclyl, such as benzothiazolyl.

R₄ and R₅ together with the nitrogen atom may be heterocyclyl, having preferably 5 or 6 ring members and having preferably 1 to 3 heteroatoms, for example N atoms; which may be unsubstituted heterocyclyl; or one or several fold substituted heterocyclyl, for example by oxo, amino, alkyl.

R₆ may be saturated or unsaturated heterocyclyl; having preferably 5 or 6 ring members and having for example 1 or 2 nitrogen hetero atoms; for example unsubstituted heterocyclyl; or one or several fold substituted heterocyclyl, for example by amino, alkyl or thiono.

R₇ may be preferably alkyl.

R₈ may be preferably alkyl or cycloalkyl.

R₉ may be preferably hydrogen or lower alkyl.

R₁₃ may be preferably alkyl.

R₁₀ may be preferably hydrogen; aryl; alkenyl; cycloalkyl; unsubstituted alkyl; substituted alkyl, for example by hydroxy, halogen, heterocyclyl, such as pyridyl, amino, for example N(alkyl)₂ or N⁺(alkyl)₃; or a group



wherein Ar denotes heterocyclyl; unsubstituted aryl; or substituted aryl, for example by hydroxy or alkoxy; preferably aryl which may be preferably phenyl.

R₉ and R₁₀ together with the nitrogen atom may be heterocyclyl having preferably 5 or 6 ring members and 1 to 3 hetero atoms such as N, S, O, for example N, O; preferably saturated heterocyclyl. Heterocyclyl includes unsubstituted heterocyclyl, or substituted heterocyclyl, for example by acyl, formyl, alkyl, for example lower alkyl. Examples include pyrrolidine, morpholine, piperazine, preferably piperazine.

R_{11} may be preferably hydrogen; unsubstituted alkyl; substituted alkyl, for example by aminoalkyl, diaminoalkyl, triaminoalkyl; aryl, such as dihydroxyphenyl; cycloalkyl; or unsubstituted heterocyclyl; or substituted heterocyclyl, for example by alkyl, thiono heterocyclyl; heterocyclyl having preferably 5 or 6 ring members and 1 to 3 hetero, preferably N atoms.

If not otherwise stated therein any carbon containing group may contain up to 20 carbon atoms, *e.g.* alkyl includes C_{1-20} , *e.g.* C_{1-8} alkyl. Lower alkyl includes *e.g.*

C_{1-4} alkyl, preferably C_{1-2} alkyl. Alkenyl includes C_{2-20} , *e.g.* C_{2-8} alkenyl. Lower alkenyl includes *e.g.* C_{3-5} alkenyl, preferably C_3 alkyl. Cycloalkyl includes, for example,

C_{3-6} cycloalkyl, particularly C_3 , C_5 or C_6 cycloalkyl. Alkyl, alkenyl and cycloalkyl include unsubstituted alkyl, alkenyl and cycloalkyl; and, substituted alkyl, alkenyl and cycloalkyl, for example, by halogen, a sulphonic acid derivative, such as SO_3H , CF_3 , hydroxy, alkoxy, acyl, alkylamino, pyridyl. Cycloalkyl is preferably unsubstituted. Acyl includes C_{1-12} , *e.g.* C_{1-6} acyl, particularly C_{1-4} acyl. Acyl includes unsubstituted acyl and substituted acyl, for example, by hydroxy, alkoxy, amino. Aryl includes phenyl. Aryl may be unsubstituted aryl or substituted aryl, for example by alkyl, alkoxy, acyl, halogen, hydroxy, unprotected or protected amino. Alkoxy includes alkoxy wherein the alkyl part is as defined above.

Heterocyclyl includes heterocyclyl having 5 or 6 ring members and 1 to 3 nitrogen, sulphur and/or oxygen hetero atoms including, for example, condensed heterocyclyl, such as for example benzthiazolyl. Heterocyclyl includes further unsubstituted heterocyclyl and substituted heterocyclyl, for example by oxo, alkoxy, hydroxy, thiono, mercapto, alkylthio, imino, alkylamino, alkylimino, amino, halogen, acyl, CF_3 , CHO, alkyl, cycloalkyl.

Carbamoyl includes the carbamoyl group or carbamoyl having alkyl and aryl residues.


Z_1 denotes unsubstituted cycloalkyl, 1,4-cyclohexadienyl, heterocyclyl or aryl; and one or several fold substituted cycloalkyl, 1,4-cyclohexadiene, heterocyclyl or aryl; for example by carboxyl, amino, nitro, cyano, lower alkyl, lower alkoxy, hydroxy, halogen, $-CO-N(Z_3Z_6)$, $-N(Z_6)-COOZ_7$, Z_6CO- , Z_6OCO- , Z_6COO- .

Z_2 denotes hydrogen; CH_2COOZ_3 ; unsubstituted lower alkyl; one or several fold substituted lower alkyl, for example by carboxyl, amino, nitro, cyano, lower alkyl, lower alkoxy, hydroxy, halogen, $-COZ_3Z_6$, $-N(Z_6)-COOZ_7$, Z_6CO- , Z_6OCO- or Z_6COO- .

Z_3 denotes hydrogen or lower alkyl.


Z_4 denotes hydrogen or an organic radical; preferably hydrogen; lower alkyl; cycloalkyl;

aralkyl; acyl; carboxyalkyl; $Z_6\text{CO}-$, $-\text{C}(Z_7Z_8)\text{COOZ}_6$ or, preferably in the case that Z_1 in group




denotes a group 2-amino-thiazol-4yl or 2-amino-thia-3,5-diazol-4yl,


Z_4 denotes a group of formula




or




or




or



or



or



wherein

Z_9 and Z_{10} independently of one another denote hydrogen or protected or unprotected carboxyl

Z_{11} denotes hydrogen or acetyl,

Z_{12} denotes unprotected or protected carboxyl,

Z_{13} denotes hydrogen or methyl,

Z_{14} denotes hydrogen; chloro; unprotected or protected carboxyl; methyl; isopropyl; hydroxy; methoxy; acetoxy,

Z_{15} and Z_{16} denote independently from one another hydrogen, hydroxy, methoxy, ethoxy, 2-methoxyethoxymethoxy, acetoxy, chloroacetoxy, butanoyloxy, methanesulfonyloxy, p-toluenesulfonyloxy, amino, acetylamino, benzyloxycarbonylamino or methanesulfonyl; or,

Z_{15} and Z_{16} denote together ethylenedioxy or carbonyldioxy,

Z_{17} denotes hydrogen, hydroxy, acetoxy, methyl, methoxy, chloroacetoxy,

with the proviso, that not all of Z_{14} , Z_{15} , Z_{16} and Z_{17} denote hydrogen,

Z_{18} and Z_{19} denote independently of one another hydrogen or methyl,

Z_{20} , Z_{21} , Z_{22} , Z_{23} and Z_{24} denote independently of one another hydrogen, halogen or hydroxy,

Z_{25} and Z_{26} denote independently from one another hydrogen; C_{1-3} alkyl; unsubstituted phenyl; or substituted phenyl,

Z_{27} denotes unsubstituted lower alkyl; or substituted lower alkyl,

Z_{28} and Z_{29} denote independently of one another hydrogen or hydroxy, and

n denotes 0 or 1,



Z_5 denotes hydrogen, alkyl, preferably lower alkyl,


Z_6 and Z_7 independently of one another denote hydrogen or alkyl, preferably lower alkyl,

Z_6 and Z_7 together with the carbon atom denote cycloalkyl, and


Z_5 and Z_6 together denote cycloalkyl.

Z_4 may be selected from the following groups:







or



For example, Ac may denote a group of formula



Preferably Ac denotes a compound of formula



wherein

W denotes CH or N


V denotes CH or N-O and

R_3 denotes hydrogen, acyl, carboxyl, alkyl.

The configuration of R_3 in group of $-C=V-R_3$ may be syn [(Z)] and anti [(E)] and is preferably syn [(Z)].

If R_3 denotes alkyl, R_3 includes unsubstituted alkyl or substituted alkyl, for example by halogen, carboxyl. Preferably W denotes CH.

In another aspect the present invention provides a compound of formula




wherein

W denotes CH or N

V denotes CH or N-O

R_1 denotes hydrogen or an ester moiety.

R_2 denotes a group of formula




wherein


Y denotes hydrogen; unsubstituted lower alkyl; or substituted lower alkyl, by the residue of a carboxylic acid, a carboxylic acid ester or a carboxylic acid amide,

R_4 denotes hydrogen, phenyl, cycloalkyl or lower alkyl

R_5 denotes hydrogen, lower alkyl, heterocyclyl or a group of formulae




IId



IIe

or



IIIf


wherein

R_7 denotes lower alkyl

R_8 denotes hydrogen, cycloalkyl or lower alkyl

R_9 denotes hydrogen or lower alkyl,

R_{10} denotes hydrogen, hydroxy; amino; phenyl; alkenyl; cycloalkyl; heterocyclyl; unsubstituted alkyl; substituted alkyl, by CF_3 , OH, alkoxy, carboxyl, halogen, amino, monoalkylamino, dialkylamino, trialkylamino, pyridyl or a sulfonic acid residue; a group of formula



wherein

R_{12} denotes hydrogen or lower alkyl,

Z denotes oxygen, sulphur, or N- R_{13} , wherein

R_{13} denotes hydrogen or lower alkyl, and


R_{11} denotes hydrogen; dihydroxyphenyl; cycloalkyl; heterocyclyl; unsubstituted lower alkyl; substituted lower alkyl by pyridyl or monoalkylamino, dialkylamino or trialkylamino; and,

R_4 and R_5 and/or R_9 and R_{10} independently of one another together with the nitrogen denote heterocyclyl,

R_6 denotes heterocyclyl, and

R_3 denotes hydrogen; acyl; carboxyl; unsubstituted alkyl; substituted alkyl by halogen or carboxyl.

In another aspect the present invention provides a compound of formula




wherein

R_{1p} is the same as R_1 in formula I,

Ac is as defined in formula I,

R_{2p} denotes a group of formulae




wherein

Y_p is the same as Y in formula IA,

R_{4p} is the same as R_4 in formula IA, and

R_{5p} denotes hydrogen, cycloalkyl, lower alkyl or a group of formula



wherein

R_{8p} is the same as R_8 in formula IA,

Z_p is the same as Z in formula IA,

R_{9p} is the same as R_9 in formula IA.


R_{7p} denotes methyl,

R_{10p} denotes hydrogen, lower alkyl or hydroxy, and

R_{4p} and R_{5p} and/or R_{9p} and R_{10p} independently of one another together with the nitrogen denote heterocyclyl, and

a compound of formulae IIbp, IIdp and IIep denote any tautomeric form, in free form, or, where such a form exists, in form of an acid addition salt, inner salt, quaternary salt or hydrate thereof.

In another aspect the present invention provides a compound of formula




wherein

Ac is as defined in formula I

R_{1q} is the same as R_1 in formula IA, and

R_{2q} denotes a group of formula




wherein

Y_q is the same as Y in formula IA,

R_{4q} is the same as R_4 in formula IA, and

R_{5q} denotes hydrogen, cycloalkyl, lower alkyl or a group of formulae



wherein

R_{7q} is the same as R_7 in formula IA,

R_{8q} is the same as R_8 in formula IA,

Z_q is the same as Z in formula IA,


R_{9q} is the same as R_9 in formula IA,

R_{10q} denotes hydrogen, lower alkyl or hydroxy, and

R_{4q} and R_{5q} and/or R_{9q} and R_{10q} independently of one another together with the nitrogen denote heterocyclyl, and

a compound of formulae IIbp, IIdp and IIep denote any tautomeric form, in free form, or, where such a form exists, in form of an acid addition salt, inner salt, quaternary salt or hydrate thereof.

In a further aspect the present invention provides a compound of formula



wherein

R_{1s} is the same as R_1 in formula IA,

V_s is the same as V in formula IA,

W_s is the same as W in formula IA


R_{3s} denotes hydrogen, lower acyl; unsubstituted alkyl; substituted lower alkyl, by

carboxyl and/or fluoro; and

R_{2s} denotes a group of formula




IIas



IIbs

or




IIcs

wherein


Y_s denotes hydrogen; unsubstituted lower alkyl; or substituted alkyl by carboxyl,

R_{4s} denotes hydrogen or lower alkyl, and

R_{5s} denotes hydrogen; saturated or unsaturated, unsubstituted heterocyclyl having 5 or 6 ring members and 1 to 3 nitrogen hetero atoms; saturated or unsaturated one or several fold substituted heterocyclyl by oxo, lower alkyl, amino or CF_3 , having 5 or 6 ring members and 1 to 3 nitrogen hetero atoms; benzothiazolyl; or a group of formula




IIds



IIes

or



IIfs

wherein

Z_s is the same as Z in formula I,

R_{7s} denotes lower alkyl,

R_{8s} denotes hydrogen, cycloalkyl or lower alkyl,

R_{9s} denotes hydrogen or lower alkyl,

R_{10s} denotes hydrogen; phenyl; allyl; cycloalkyl; unsubstituted alkyl; substituted alkyl by CF_3 , dialkylamino, trialkylamino, hydroxy, pyridyl or SO_3H , and


R_{11s} denotes hydrogen; pyridyl; cycloalkyl; unsubstituted lower alkyl;

substituted lower alkyl by pyridyl or trialkylamino; saturated or unsaturated heterocyclyl having 5 or 6 ring members and 1 to 3 nitrogen hetero atoms; or one or several fold substituted heterocyclyl by lower alkyl and/or thiono, having 5 or 6 ring members and 1 to 3 nitrogen hetero atoms;

R_4 , and R_5 , together with the nitrogen atom denote heterocyclyl selected from saturated, unsubstituted heterocyclyl having 5 or 6 ring members and 1 or 2 nitrogen hetero atoms; saturated, one or several fold substituted heterocyclyl by oxo or lower alkyl, having 5 or 6 ring members and 1 or 2 nitrogen hetero atoms; and/or

R_9 , and R_{10} , together with the nitrogen atom denote saturated, unsubstituted heterocyclyl having 5 or 6 ring members and 1 or 2 nitrogen and/or oxygen hetero atoms; unsaturated, one or several fold substituted heterocyclyl by CHO or lower alkyl, having 5 or 6 ring members and 1 or 2 nitrogen and/or oxygen hetero atoms.

In another aspect the present invention provides a compound of formula




wherein

W denotes CH or N

V denotes CH or N-O

R_1 denotes hydrogen or an ester moiety, and

R_2 denotes a group of formula




IIb

wherein

R_4 is as defined in claim 1 and

R_5 denotes a group of formula



wherein

Z denotes $-\text{N}-\text{R}_{13}$, wherein

R_{13} is as defined in claim 1, and

R_9 and R_{10} together with the nitrogen atom denote heterocyclyl which is a piperazinyl.

In another aspect the present invention provides a compound selected from


7-[(2-amino-4-thiazolyl)-(Z)-(hydroxyimino)acetyl]amino]-3-[(aminoiminomethyl)-hydrazono]methyl]-3-cephem-4-carboxylic acid (compound of Example 2),

7-[(2-amino-4-thiazolyl)-(Z)-(hydroxyimino)acetyl]-amino]-3-[(piperazinoiminomethyl)-hydrazono]methyl]-3-cephem-4-carboxylic acid (compound of Example 96)

7-[(5-Amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluormethoxyimino)acetyl]amino]-3-[[[(piperazinoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid (compound of Example 139).

A compound of formulae I, IA, I_p, I_q, I_r, IVi, IVa and VIa may exist in equilibrium with tautomeric forms. The present invention includes a compound of formulae I, IA, I_p, I_q, I_r, IVi, IVa and VIa in any tautomeric form in which it may exist.

In another aspect the present invention provides a process for the production of a compound of formula I by reaction of a compound of formula



wherein Ac is as defined in formula I and

a) either

α) R_b denotes hydroxy and R_c and R_d together form a bond, or

β) R_d denotes hydrogen, a cation, an ester forming group or a silyl group, and

R_b and R_c together denote oxo,


in free form or in form of an acid addition salt

with a group of formula



wherein R_2 is as defined in formula I, or

b) reacting a compound of formula



wherein R_1 and R_2 are as defined in formula I, with a compound of formula



wherein Ac is as defined in formula I and X' denotes a leaving group.

If desired reactive groups may be protected with protecting groups, which may be, or,

which are split off under the reaction conditions, or after termination of the reaction described above. A compound of formula I wherein R_1 denotes hydrogen may be converted into a compound of formula I, wherein R_1 denotes an carboxylic acid ester group. A compound of formula I may be isolated from the reaction mixture in conventional manner.

Process a) may be carried out as follows:

A compound of formula III in a solvent which is inert under the reaction conditions, such as water, a mixture of water and a lower alcohol and/or dioxane, or a dipolar aprotic solvent, for example dimethylformamide or dimethylsulfoxide, optionally mixed with an alcohol or water is reacted with a compound of formula IV at a temperature of about -20 to 50° C. An optimal pH may be adjusted by addition of an inorganic or organic acid or base. A compound of formula I thus obtained may be isolated in conventional manner, for example by addition of an anti-solvent or by chromatographic techniques.

Process b) may be carried out as follows:

The reaction may be carried out as conventional, *e.g.* a compound of formula VI may be reacted with a compound of formula VII in a solvent, for example dissolved or suspended in a mixture of acetone/water, for example at room temperature.


A reactive group may be protected, preferably by silyl protecting group technology.

Suitable solvents include solvents which are inert under the reaction conditions, such as chlorinated hydrocarbons, nitriles, such as acetonitrile, ethers, such as tetrahydrofuran or a mixture of such solvents. Further suitable solvents include dipolar aprotic solvents, *e.g.*

N,N-dimethylformamide. Protecting groups may be split off in conventional manner.

A starting compound of formula II may, for example, be obtained by

a) reaction of a compound of formula




wherein either

α) R_a denotes a salt of $-NH_2$ with an inorganic or organic acid, R'_b denotes hydroxy, and

R'_c and R'_d denote together a bond, or

β) R_a denotes NH_2 , R'_d denotes hydrogen and R'_b and R'_c together denote oxo, with a silylation agent and,

a compound obtained in step a) of formula



wherein Sil denotes a silyl group and either

α) R''_b denotes $-OSil$ and R''_c and R''_d together denote a bond


β) R''_d denotes Sil and R''_b and R''_c together denote oxo

is acylated either directly in the reaction mixture or after isolation from the reaction mixture.

Acylation may be carried out in conventional manner.

A compound of formula IIIc may be obtained


a) for the production of a compound of formula



which is in the form of a salt of an inorganic or organic acid and wherein

R'''_b denotes hydroxy and R'''_c and R'''_d together denote a bond,

reacting a salt of an inorganic or organic acid of a compound of formula




wherein

R_{14} and R_{15} are the same or different and each denote hydrogen or an organic residue

in an organic solvent optionally in the presence of water with ozone

b) for the production of a compound of formula



treating a compound of formula IIIe wherein R''_b , R''_c and R''_d as defined above, with a base.

Compounds of formulae IV are partially new and may be obtained analogously to conventional methods, or, as described in the examples.

In another aspect the present invention provides a compound of formula



wherein


R_{2i} denotes a group of formula



wherein

R_{4i} is the same as R_4 in formula I and denotes preferably hydrogen or alkyl and

R_{5i} denotes a group of formula



wherein


Z_i denotes $N-R_{13i}$, wherein

R_{13i} is the same as R_{13} in formula I and denotes preferably hydrogen or alkyl, and

R_{9i} and R_{10i} together with the nitrogen atom denote heterocyclyl which is a piperazinyl; or

R_{4i} is the same as R_4 in formula I and denotes preferably hydrogen, and

R_{5i} denotes a group of formula




wherein

R_{8i} denotes alkyl, preferably at least C_2 alkyl; or cycloalkyl, preferably cyclopropyl, and

R_{7i} denotes alkyl, preferably methyl; or

R_{4i} is the same as R_4 in formula I and denotes preferably hydrogen or alkyl and

R_{5i} denotes a group of formula



wherein

Z_i denotes $N-R_{13i}$, wherein


R_{13i} denotes hydrogen, alkyl or cycloalkyl, preferably hydrogen or alkyl

R_{9i} denotes hydrogen and

R_{10i} denotes CH_2CF_3 , $C(CH_3)_3$, OH or an alkyl group having at least 2 carbon atoms which is substituted by dialkyl amine or trialkyl ammonium, hydroxy; or

R_{4i} is the same as R_4 in formula I and denotes preferably hydrogen

R_{3i} denotes a group of formula



wherein


Z_i denotes $N-R_{13i}$, wherein

R_{13i} denotes alkyl or cycloalkyl, preferably alkyl, and

R_{9i} and R_{10i} together with the nitrogen atom denote heterocyclyl which is morpholyl or pyrrolidinyl; or

R_{4i} is the same as R_4 in formula I and denotes preferably hydrogen

R_{3i} denotes a group of formula



wherein

Z_i denotes $N-R_{13i}$, wherein


R_{13i} denotes hydrogen, alkyl or cycloalkyl, preferably hydrogen, and

R_{9i} denotes hydrogen, and

R_{10i} denotes cycloalkyl, preferably cyclopropyl; or

R_{4i} is the same as R_4 in formula I and denotes preferably hydrogen

R_{5i} denotes a group of formula



wherein

Z_i denotes $N-R_{13i}$, wherein

R_{13i} is the same as R_{13} in formula I and denotes preferably hydrogen,

R_{9i} denotes hydrogen or alkyl, preferably hydrogen, and


R_{10i} denotes a group



wherein Phe denotes phenyl, preferably a dihydroxy phenyl, or

R_{4i} is the same as R_4 in formula I and denotes preferably hydrogen

R_{5i} denotes a group of formula



wherein


Z_1 denotes $N-R_{13i}$, wherein

R_{13i} denotes hydrogen, alkyl or cycloalkyl, preferably hydrogen,


R_{11i} denotes a dihydroxyphenyl or substituted pyrrolidyl by alkyl; or

Z_1 denotes oxygen and

R_{11i} denotes the group of formula




In another aspect the present invention provides a compound of formula




wherein






R_x is a group of formula



or




25

 R_y is NH and R_z is hydrogen; or R_x is a group of formula R_y is NH and R_z is CH_3 ; or R_x is $-\text{SCH}_3$ R_y is a group of formula

and


 R_z is hydrogen, or R_x is a group of formula



R_y is N—CH_3 and

R_z is hydrogen; or


R_x is the group



R_y is $\text{N—C}_2\text{H}_5$ and

R_z is hydrogen; or

R_x is the group




R_y is oxygen and

R_z is hydrogen.

Compounds of formulae VI are partially new and may be obtained analogously to conventional methods, or, as described in the examples.

In another aspect the present invention provides a compound of formula



wherein

R_1 is as defined in formula I and

R_{xx} denotes the group



wherein

R_x , R_y and R_z as defined above.

In this specification unless otherwise indicated terms such as "compound of formula I, IA, I_r, I_p, I_q, IVi, IVa and VIa" embrace the compound in any form, for example in salt form and free base form. The present invention thus includes a compound in free or base form or, where such forms exist, in salt form, for example in form of an acid addition salt, inner salt, quaternary salt and/or in solvate, for example hydrate form thereof. A salt may be a pharmaceutically acceptable salt of a compound of formulae I, IA, I_r, I_p, I_q such as a metal salt or an amine salt. Metal salts include for example sodium, potassium, calcium, barium, zinc, aluminum salts, preferably sodium or potassium salts. Amine salts include for example trialkylamine, procaine, dibenzylamine and benzylamine salts. A free form of a compound of formulae I, IA, I_r, I_p, I_q, IVi, IVa and VIa may be converted into a salt form and *vice versa*.

In a further aspect the present invention provides a compound of formulae I, IA, I_r, I_p, I_q, IVi, IVa and VIa in free form; or in salt form, for example in acid addition salt form or in metal salt form; and a compound of formulae I, IA, I_r, I_p, I_q, IVi, IVa and VIa in solvate form.

A compound of formula I may also be obtained analogously to other processes conventional in the β -lactam chemistry.

The compounds of formula I, hereinafter designated as "active compound(s) of the invention" exhibits pharmacological activity and are therefore useful as pharmaceuticals. In particular, the active compounds of the invention show antimicrobial, e.g. antibacterial, activity against gram negative and gram positive bacteria such as *Pseudomonas*, e.g. *Pseudomonas aeruginosa*, *Pseudomonas fluorescens*; *Enterobacter*, e.g. *Enterobacter cloacae*; *Enterococcus*, e.g. *Enterococcus faecalis*; *Moraxella*, e.g. *Moraxella catarrhalis*; *Haemophilus*, e.g. *Haemophilus influenza*; *Klebsiella*, e.g. *Klebsiella edwardsii*, *Klebsiella pneumoniae*; *Streptococcus*, e.g. *Streptococcus pneumoniae*, *Streptococcus durans*, *Streptococcus faecium*, *Streptococcus pyogenes*; *Staphylococcus*, e.g. *Staphylococcus aureus*, *Staphylococcus pyogenes*; *Escherichia*, e.g. *Escherichia coli*; and *Proteus*, e.g. *Proteus mirabilis* *in vitro* in the Agar Dilution Test according to National Committee for Clinical Laboratory Standards (NCCLS) 1993, Document M7-A3Vol.13, No. 25: "Methods for dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Third Edition, Approved Standard" and *in vivo* in the septikaemic mouse model. The active compounds of the invention show activity in the mouse when administered at dosages from about 0.05 to 50 mg/kg body weight (ED_{50} values). The active compounds show an MHK (μ g/ml) in the Agar Dilution Test from about 0.005 to ca. 50. The active compounds of the invention show an surprising overall activity spectrum.

It has, for example, been determined that the MHK (μ g/ml) of the compound of Example 139 against, for example *Enterococcus faecalis* strains ATTC 29212 or ATCC 51299, is of ca. 0.08 to 0.25; against *Staphylococcus aureus* strains ATCC 29213 or ATCC 9144 is of ca. 0.2 to 0.4 and against *Pseudomonas aeruginosa* strain 27853 is ca. 0.8.

The active compounds of the invention are, therefore, useful for the treatment of microbial, e.g. bacterial diseases.

In another aspect the present invention provides a compound of claim 1 for use as a pharmaceutical, preferably as an antimicrobial agent, such as an antibiotic.

In a further aspect the present invention provides a compound of claim 1 for use in the preparation of a medicament for the treatment of microbial diseases, for example of diseases caused by bacteria selected from *Pseudomonas*, *Enterobacter*, *Enterococcus*, *Moraxella*, *Haemophilus*, *Klebsiella*, *Streptococcus*, *Staphylococcus*, *Escherichia*, and *Proteus*.

In a further aspect the present invention provides a method of treatment of microbial diseases which comprises administering to a subject in need of such treatment an effective amount of a compound of formula I.

For this indication, the appropriate dosage will, of course, vary depending upon, for example, the compound of formula I employed, the host, the mode of administration and the nature and severity of the conditions being treated. However, in general, for satisfactory results in larger mammals, for example humans, an indicated daily dosage is in the range from about 0.05 to 5 g, for example 0.1 to about 2.5 g, of an active compound of the invention conveniently administered, for example, in divided doses up to four times a day.

An active compound of the invention may be administered by any conventional route, for example orally, *e.g.* in form of tablets or capsules, or parenterally in the form of injectable solutions or suspensions, *e.g.* in analogous manner to cefotaxime.

The compound 7-[[[(5-Amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)acetyl]amino]-3-[[[(piperazinoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid (compound of Example 139) is the preferred compound of the invention for use as an antimicrobial agent.

It has, for example been determined that the MHK ($\mu\text{g/ml}$) of the compound of Example 139 (tested in form of the trihydrochloride) against, for example *Streptococcus pneumoniae*, strain ATCC 49619 is ca. 0.01 whereas, for example ceftriaxone shows an MHK ($\mu\text{g/ml}$) of ca. 0.02. It is therefore, indicated that for the treatment of microbial diseases, *e.g.* bacterial diseases the preferred compounds of the invention may be administered to larger mammals, for example humans, by similar modes of administration at similar dosages than conventionally employed with ceftriaxone.

The compounds of formula I may be administered in pharmaceutically acceptable salt form, *e.g.* acid addition salt form or base addition salt form or in the corresponding free forms, optionally in solvate form. Such salts exhibit the same order of activity as the free forms.

The present invention also provides pharmaceutical compositions comprising a compound of formula I in pharmaceutically acceptable salt form or free form in association with at least one pharmaceutical carrier or diluent.

Such compositions may be manufactured in conventional manner.

Unit dosage form may contain, for example 10 mg to about 1 g, for example 10 mg to about 700 mg.

In the following Examples the temperatures indicated are in degree Celsius.

Example 1

Dihydrochloride of 7-[(2-Amino-4-thiazolyl)-(Z)-(methoxyimino)acetyl]amino-3-[[[(aminoimino-methyl)hydrazono]methyl]-3-cephem-4-carboxylic acid (Process a)

1.24 g of the hydrogen carbonate of aminoguanidine are dissolved in 9.15 ml of 2 N HCl and added under stirring to a solution of 3.2 g of the trifluoroacetate of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-(2-aminothiazol-4-yl)-(Z)-2-methoxyimino acetic acid amide in 125 ml of 4% aqueous acetonitrile. After ca. 90 minutes the precipitated dihydrochloride of 7-[(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino-3-[[[(aminoimino-methyl)hydrazono]methyl]-3-cephem-4-carboxylic acid is filtered off, washed with acetonitrile and dried.

Example 2

Dihydrochloride of 7-[[[(2-Amino-4-thiazolyl)-(Z)-(hydroxyimino)acetyl]amino]-3-[[[(amino-iminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid (Process a)

- a) 10 g of the hydrochloride of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-(2-aminothiazol-4-yl)-(Z)-2-(acetoxymino)-acetic acid amide are suspended in 160 ml of acetonitrile and treated with 53 ml of water and 11 ml of 8 N HCl. The reaction mixture is stirred for ca. 14 hours at room temperature. A clear solution is obtained in which the acetoxymino group being hydrolyzed to give the hydroxyimino group.
- b) 3 g of the hydrogen carbonate of aminoguanidine are dissolved in 11 ml of 1 N HCl and added dropwise to the solution obtained in step a) which is cooled to 0°. After ca. 30 minutes the reaction mixture is warmed to room temperature and stirred for ca. another 2.5 hours. The dihydrochloride of 7-[[[(2-Amino-4-thiazolyl)-(Z)-(hydroxyimino)acetyl]amino]-3-[[[(amino-iminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid precipitate, is filtered off, washed with a mixture of acetonitrile and water, acetonitrile and with ether and dried.








Example 3











Sodium salt of 7-[(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino-3-[(methoxyimino)methyl]-3-cephem-4-carboxylic acid (Process b)

0.5 g of 7-amino-3-[(methoxyimino)methyl]-3-cephem-4-carboxylic acid and 0.75 g of (2-amino-4-thiazolyl)(methoxyimino)acetic acid mercaptobenzthiazolyl ester are suspended in a mixture of 2.4 ml of water and 4.8 ml of acetone. Ca. 1.8 ml of 2N sodium hydroxide solution are added dropwise in such a way that a pH of 8.0 is kept. The reaction mixture is stirred at 20° for ca. 1 hour. 2.4 ml of acetone are added dropwise. A clear solution is obtained within 3 hours. 120 ml of acetone are slowly added. A suspension is obtained which is cooled to 0°. After ca. 5 hours the precipitate formed is filtered off and redissolved in 4 ml of water. The clear solution is treated with 0.2 g of active charcoal and stirred for ca. 15 minutes. Active charcoal is filtered off and 100 ml of acetone are added within ca. 1 hour at 0°. The sodium salt of 7-[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino-3-[(methoxyimino)methyl]-3-cephem-4-carboxylic acid is obtained in form of colourless crystals, which are filtered off, washed with ca. 5 ml of acetone and dried.









The compounds of the following TABLE 1 of formula IA (V is =N-O- in all of the Examples; and W is CH in Examples 4 to 68 and 70 to 138; and W is N in Examples 69 and 139 of TABLE 1) may be obtained in analogous manner to that described in Examples 1 to 3. Salt forms are exemplified. The configuration of R₃ in group - C = N - R₃ is syn [(Z)].









Table 1









Ex-ample	R ₃	R ₂	R ₁	Salt
4	CH ₃	OH	H	-
5	-CH ₂ COOH		H	2HCl
6	CH ₃	-OCH ₂ COONa	Na	-
7	CH ₃	-NH-CO-NH ₂	H	-
8	CH ₃		H	2HCl
9	CH ₃	-NH-C ₆ H ₅	H	-
10	COCH ₃		H	2HCl
11	CH ₃		H	2HCl
12	CH ₃		H	2HCl
13	CH ₃		H	2HCl
14	CH ₃		H	2HCl








15	CH ₃		H	2HCl
16	H		H	2HCl
17	H		H	2HCl
18	H		H	2HCl
19	H		H	2HCl
20	CH ₃		H	2HCl
21	CH ₃		H	HCl
22	CH ₃		H	HCl
23	CH ₃		H	HCl
24	CH ₃		H	2HCl









25	CH ₃		H	2HCl
26	CH ₃		H	2HCl
27	CH ₃		H	2HCl
28	CH ₃		H	HCl
29	CH ₃		H	2HCl
30	CH ₃		H	2HCl
31	CH ₃		H	2HCl
32	CH ₃		H	2HCl
33	CH ₃		H	2HCl










34	CH ₃		H	Cl ⁻
35	CH ₃		H	2HCl
36	CH ₃		H	2HCl
37	CH ₃		H	2HCl
38	CH ₃		H	2HCl
39	CH ₃		H	2HCl
40	CH ₃		H	2HCl
41	CH ₃		H	HCl










42	CH ₃		H	3HCl
43	CH ₃		H	2HCl
44	CH ₃		H	HCl
45	CH ₃		H	2HCl
46	CH ₃		H	3HCl
47	CH ₃		H	2HCl
48	CH ₃		H	2HCl
49	CH ₃		H	HCl

50	CH ₃		H	2HCl
51	CH ₃		H	Cl ⁻
52	CH ₃		H	HCl
53	CH ₃		H	2HCl
54	CH ₃		H	2HCl
55	CH ₃		H	2HCl
56	CH ₃		H	HCl
57	CH ₃		H	2HCl

58	CH ₃		H	2HCl
59	CH ₃		H	2HCl
60	CH ₃		H	2HCl
61	CH ₃		H	HCl
62	CH ₃		H	Cl- 2HCl
63	CH ₃		H	Cl- 2HCl
64	CH ₃		H	HCl










65	CH ₃		H	HCl
66	CH ₃		H	3HCl
67	CH ₃		H	2HCl
68	CH ₃		H	2HCl
69	CH ₂ F		H	2HCl
70	H		H	2HCl
71	H		H	HCl
72	H		H	HCl








73	H		H	2HCl
74	H		H	2HCl
75	H		H	2HCl
76	H		H	2HCl
77	H	OCH ₃	H	HCl
78	H		H	2HCl
79	H		H	2HCl
80	H		H	2HCl
81	H		H	2HCl
82	H		H	2HCl

83	H		H	2HCl
84	H		H	2HCl
85	H		H	2HCl
86	H		H	2HCl
87	H		H	2HCl
88	H		H	HCl
89	H		H	HCl
90	H		H	2HCl
91	H		H	HCl




92			H	2HCl
93	H		H	2HCl
94	H		H	2HCl
95	H		H	2HCl
96	H		H	3HCl
97	H		H	2HCl
98	H		H	2HCl
99	H		H	2HCl
100	H		H	2HCl

101	CH_3	$-\text{NH}-\text{CH}=\text{NH}$	H	2HCl
102	$\begin{array}{c} \text{CH}_3 \\ \\ -\text{C}-\text{COOH} \\ \\ \text{CH}_3 \end{array}$	$-\text{NH}-\text{C} \begin{array}{l} \nearrow \text{NH}_2 \\ \searrow \text{NH} \end{array}$	H	2HCl
103	$\begin{array}{c} \text{CH}_3 \\ \\ -\text{C}-\text{COOH} \\ \\ \text{CH}_3 \end{array}$	$-\text{NH}-\text{C} \begin{array}{l} \nearrow \text{NH}-\text{OH} \\ \searrow \text{NH} \end{array}$	H	2HCl
104	$\begin{array}{c} \text{CH}_3 \\ \\ -\text{C}-\text{COOH} \\ \\ \text{CH}_3 \end{array}$	$-\text{NH}-\text{C} \begin{array}{l} \nearrow \text{NH}-\text{CH}_2 \\ \searrow \text{NH} \end{array} \text{C}_5\text{H}_5$	H	2HCl
105	$\begin{array}{c} \text{CH}_3 \\ \\ -\text{C}-\text{COOH} \\ \\ \text{CH}_3 \end{array}$	$-\text{NH}-\text{C} \begin{array}{l} \nearrow \text{NH} \\ \searrow \text{NH} \end{array} \text{C}_3\text{H}_5$	H	2HCl
106	$\begin{array}{c} \text{CH}_3 \\ \\ -\text{C}-\text{COOH} \\ \\ \text{CH}_3 \end{array}$	$-\text{NH}-\text{C} \begin{array}{l} \nearrow \text{N}-\text{CH}_3 \\ \searrow \text{NH}-\text{CH}_3 \end{array}$	H	2HCl
107	$\begin{array}{c} \text{CH}_3 \\ \\ -\text{C}-\text{COOH} \\ \\ \text{CH}_3 \end{array}$	$-\text{NH}-\text{C} \begin{array}{l} \nearrow \text{NH} \\ \searrow \text{N} \end{array} \text{C}_4\text{H}_8$	H	2HCl

108	CH ₃		H	2HCl
109	CH ₂ COOH		H	2HCl
110	CH ₂ COOH		H	2HCl
111	CH ₂ COOH		H	2HCl
112	H		H	2HCl
113	H		H	2HCl
114	H		H	2HCl
115	H		H	2HCl
116	H		H	3HCl

117	H		H	Cl- 2HCl
118	H		H	2HCl
119	H		H	2HCl
120	H		H	2HCl
121	H		H	Cl- 2HCl
122	H		H	3HCl
123	H		H	2HCl

124	H		H	2HCl
125	H		H	3HCl
126	H		H	3HCl
127	H		H	3HCl
128	H		H	3HCl
129	CH ₃		H	HCl
130	CH ₃		H	HCl
131	CH ₃		H	2HCl
132	CH ₃		H	2HCl

133	CH ₃	$\text{—NH—C(=S)—NH—(CH}_2\text{)}_2\text{—SO}_3\text{H}$	H	-
134	H	—NH—C(=S)—NH— 	H	HCl
135	H	$\text{—NH—C(=S)—NH—(CH}_2\text{)}_3\text{—CH}_3$	H	HCl
136	CH ₃	—NH—C(=S)—N—  —N—CH_3	H	2HCl
137	CH ₃	$\begin{array}{c} \text{S} \\ \parallel \\ \text{—N—C—NH}_2 \\ \\ \text{CH}_3 \end{array}$	H	HCl
138	CH ₃	$\text{—NH—COC(CH}_3\text{)}_3$	H	HCl
139	CH ₂ F	—NH—C(=NH)—N—  —NH	H	3HCl

Example 140**Dihydrochloride of 7-[2-(2-aminothiazol-4-yl)-(Z)-2-pentenylamino]-3-[[aminoimino-methyl]hydrazono]methyl]-3-cephem-4-carboxylic acid**

1 g of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-[2-(tert.-butoxycarbonylamino)thiazol-4-yl]-(Z)-2-pentenoic acid amide is dissolved in a mixture of 30 ml of methanol and 30 ml of acetonitrile and 0.3 g of the hydrogencarbonate of aminoguanidine are added. A pH of 2.0 is adjusted by addition of methanolic HCl. Stirring is continued at room temperature. Within ca. 30 minutes a light coloured precipitate forms, which is filtered off after ca. 3 hours, washed with acetonitrile and ether and dried. The dihydrochloride of 7-[2-(2-aminothiazol-4-yl)-(Z)-2-pentenylamino]-3-[[aminoimino-methyl]hydrazono]methyl]-3-cephem-4-carboxylic acid is obtained in the form of a light yellow powder.

Example 141**Trifluoroacetate of 7-[(2-Amino-4-thiazolyl)-(Z)-(methoxyimino)acetyl]amino-3-(hydrazonomethyl)-3-cephem-4-carboxylic acid**

A suspension of 3 g of 7-[(2-amino-4-thiazolyl)-(Z)-(methoxyimino)acetyl]amino-3-[[2-(1,1-dimethylethoxy)-2-oxoethoxy]hydrazonomethyl]-3-cephem-4-carboxylic acid in 75 ml of methylenechloride is treated at ca. 0° with 0,6 ml of anisol. 10 ml of trifluoro acetic acid are added dropwise under stirring. The solution obtained is stirred for ca. further 3 hours at 0°. The reaction mixture is poured into 600 ml of ether. The trifluoroacetate of 7-[(2-Amino-4-thiazolyl)-(Z)-(methoxyimino)acetyl]amino-3-(hydrazono)-3-cephem-4-carboxylic acid precipitates, is filtered off and dried.

Example 142**Hydrobromide of 7-[(2-amino-4-thiazolyl)-(Z)-(methoxyimino)acetyl]amino-3-[(4-methylthiazol-2-yl)hydrazonomethyl]-3-cephem-4-carboxylic acid**

1 g of 7-[(2-amino-4-thiazolyl)-(Z)-(methoxyimino)acetyl]amino-3-[(aminothioxomethyl)-hydrazonomethyl]-3-cephem-4-carboxylic acid is suspended in 30 ml of acetonitrile and stirred after addition of 2.5 ml of N,O-bis(trimethylsilyl)acetamide for

ca. 20 minutes. The clear solution obtained is treated with 0.6 g of bromoacetone and stirred overnight. 1 ml of water are added. The precipitate is filtered off and dried. The hydrobromide of 7-[(2-amino-4-thiazolyl)-(Z)-(methoxyimino)acetyl]amino-3-[(4-methylthiazol-2-yl)hydrazonomethyl]-3-cephem-4-carboxylic acid is obtained as a yellow solid.

Example 143

Hydrobromide of 7-[(2-amino-4-thiazolyl)-(Z)-(methoxyimino)acetyl]amino-3-[(4-methylthiazol-2-yl)methylhydrazonomethyl]-3-cephem-4-carboxylic acid

1 g of 7-[(2-amino-4-thiazolyl)-(Z)-(methoxyimino)acetyl]amino-3-[(aminothioxomethyl)-methylhydrazonomethyl]-3-cephem-4-carboxylic acid is reacted in analogous manner as described in Example 142 with N,O-bis(trimethylsilyl)acetamide and with bromoacetone. The hydrobromide of 7-[(2-amino-4-thiazolyl)-(Z)-(methoxyimino)-acetyl]amino-3-[(4-methylthiazol-2-yl)methylhydrazonomethyl]-3-cephem-4-carboxylic acid is obtained as a yellow solid.

Example 144

Dihydrate of 6R-trans (Z)-7-[(2-Amino-4-thiazolyl)(methoxyimino)-acetyl]amino-3-[[[(imino(methylamino)methyl)hydrazono]methyl]-3-cephem-4-carboxylic acid

1.1 g of the dihydrochloride obtained according to Example 8 are dissolved in 25 ml of water, treated with 0.5 g of active charcoal and stirred for ca. 5 minutes. The almost colourless filtrate is poured into 5 ml of water under stirring. A pH of about 7 is kept by addition of 2.5% aqueous ammonia. The precipitate obtained is filtered off and dried. The dihydrate of 6R-trans (Z)-7-[(2-Amino-4-thiazolyl)-(methoxyimino)-acetyl]amino-3-[[[(imino(methylamino)methyl)hydrazono]methyl]-3-cephem-4-carboxylic acid is obtained as a yellowish powder.

Example 145

6R-trans (Z)-7-[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino-3-[[[(imino(methylamino)methyl)hydrazono]methyl]-3-cephem-4-carboxylic acid 1-(isopropoxycarbonyloxy)ethyl ester

5.5 g of the dihydrate obtained according to Example 144 are dissolved in 55 ml of

dimethylacetamide under addition of 1.43 ml tetramethylguanidine. This solution is cooled to 0°, treated with a solution of 4.4 g of 1-iodoethyl-isopropylcarbonate in 30 ml of toluene and stirred for ca. 90 minutes at 0°. The reaction mixture is poured into 1 liter of diethylether. The precipitate obtained is filtered off and stirred twice each with 500 ml of acetonitrile. The acetonitrile phases are combined, filtered and evaporated to a volume of ca. 10 ml. The oily residue is treated with 400 ml of water. A precipitate forms which is filtered off and dried. The precipitate is stirred with 700 ml of ethyl acetate. After evaporation of the ethyl acetate yellow coloured 6R-trans (Z)-7-[(2-amino-4-thiazolyl)-(methoxyimino)acetyl]amino-3-[[imino(methylamino)methyl]hydrazono]methyl]-3-cephem-4-carboxylic acid 1-(isopropoxycarbonyloxy)ethyl ester is obtained in the form of a diastereomeric mixture in the ratio of ca. 1:1.

Example 146

6R-trans (Z)-7-[[[(Acetoxyimino)-2-amino-4-thiazolyl]acetyl]amino-3-[[[(aminoimino)methyl]hydrazono]methyl]-3-cephem-4-carboxylic acid 1-(isopropoxycarbonyloxy) ethyl ester

0,72 g of the hydrogen carbonate of aminoguanidine are dissolved in 5.2 ml of 2 N HCl. This solution is added to a solution of 2 g of 6R-trans (Z)-7-[[[(acetoxyimino)-2-amino-4-thiazolyl]acetyl]amino-3-formyl-3-cephem-4-carboxylic acid 1-(isopropoxycarbonyloxy)ethyl ester in 14 ml of acetonitrile containing 1.3 ml of water. The reaction mixture is stirred for ca. 45 minutes at room temperature and poured into 100 ml of acetonitrile. The precipitate formed is filtered off and dissolved in 100 ml of water. The pH of the solution obtained is adjusted to 7 by addition of 0.5 N aqueous sodium hydrogen carbonate. A yellow suspension is obtained which is extracted twice with a mixture of 200 ml of ethyl acetate and 40 ml of acetonitrile. The organic phases are combined, dried over Na₂SO₄ and evaporated. 6R-trans (Z)-7-[[[(acet-oxyimino)-2-amino-4-thiazolyl]acetyl]amino-3-[[[(aminoiminomethyl)hydrazono]-methyl]-3-cephem-4-carboxylic acid 1-(isopropoxycarbonyloxy) ethyl ester is obtained in the form of a yellow diastereomeric mixture in the ratio of ca. 1:1.

Example 147

Ditosylate of 6R-trans (Z)-7-[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]amino-3-[[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid (isopropoxycarbonyloxy)ethyl ester

A solution of 0.6 g of a compound obtained according to Example 146 in a mixture of 50 ml of acetonitrile and 20 ml of isopropanol is treated with 0.66 g of the monohydrate of toluene-4-sulfonic acid and stirred overnight at 25°. The reaction mixture is poured into 150 ml of tert.butyl-methylether. The precipitate obtained is filtered off, washed with tert.butyl-methylether and dried. The ditosylate of 6R-trans (Z)-7-[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]amino-3-[[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid (isopropoxycarbonyloxy)ethyl ester is obtained in the form of a light coloured diastereomeric mixture in the ratio of ca. 1:1.

Example 148

Dihydrochloride of 7-[(2-amino-4 thiazolyl)-(Z)-[(carboxymethoxy)imino]actyl]-amino]-3-[[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid (Compound of Example 5)

a) Dihydrochloride of 7-Amino-3-[[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid

To 1.0 g of 7-amino-3-formyl-3-cephem-4-carboxylic acid in a mixture of 50 ml of acetonitrile and 5 ml of 2N HCl are added dropwise 0.6 g of the hydrogen carbonate of aminoguanidine, dissolved in 2.2 ml of 2N HCl. The dihydrochloride of 7-amino-3-[[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid precipitates, is filtered off, washed with acetonitrile and dried.

b) Hydrochloride of 7-[(2-amino-4-thiazolyl)-(Z)-[[2-(1,1-dimethylethoxy)-2-oxoetoxy]imino]acetyl]amino]-3-[[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid

4 g of the dihydrochloride of 7-amino-3-[[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid are dissolved in 80 ml of methanol. The solution is cooled

to 0° and treated with a solution of 7 g of (2-amino-4-thiazolyl)-(Z)-[2-(1,1-dimethylethoxy)-2-oxoethoxy]imino]thioacetic acid S-benzothiazol ester in 50 ml of methylene chloride. The reaction mixture is stirred for about 2.5 hours at 20°. About a third of the solvent is evaporated off and 120 ml of ether are added to the residue. The hydrochloride of 7-[[[(2-amino-4-thiazolyl)-(Z)-[[2-(1,1-dimethylethoxy)-2-oxoethoxy]imino]-acetyl]amino]-3-[[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid precipitates, is filtered off, washed with ether and dried.

c) Dihydrochloride of 7-[[[(2-amino-4 thiazolyl)-(Z)-[(carboxymethoxy)imino]actyl]-amino]-3-[[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid
3.5 g of the hydrochloride of 7-[[[(2-amino-4-thiazolyl)-(Z)-[[2-(1,1-dimethylethoxy)-2-oxoethoxy]imino]acetyl]amino]-3-[[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid are dissolved in 20 ml of trifluoroacetic acid at 0°. The solution is stirred for ca. 15 minutes at 0° and for ca. 1 hour at 20°. The reaction mixture is treated with 40 ml of ether. A precipitate forms, is filtered off, washed with ether, dried, dissolved in 15 ml of 2N HCl and stirred for ca. 1 hour at 20°. A light brownish precipitate of the dihydrochloride of 7-[[[(2-amino-4 thiazolyl)-(Z)-[(carboxy-methoxy)imino]actyl]-amino]-3-[[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid is obtained, filtered off and dried.

The compounds of Examples 1 to 146 may be obtained as described in Example 147 using the appropriate starting material.

Compounds used as starting material may be prepared as follows:

Example A)

Trifluoroacetate of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-(2-aminothiazol-4-yl)-(Z)-2-methoxyiminoacetic acid amide

a) Hydrochloride of 6-amino-1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]thiazin (hydroxylactone of the hydrochloride of 7-amino-3-formyl-3-cephem-4-carboxylic acid)

13.8 g of the hydrochloride of 7-amino-3-[(Z/E)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid are dissolved in 200 ml of methanol. The solution is cooled to -50° and 8 l of O_2 containing ca. 2 percent v/v ozone are introduced per minute under stirring at this temperature. After ca. 20 minutes the hydrochloride of 6-amino-1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-aceto[2,1-b]furo[3,4-d][1,3]thiazin being practically quantitatively formed and ozonolysis is terminated as determined by HPLC. 8 l of N_2 are bubbled through the reaction mixture within ca. 2 minutes. The slight cloudy solution is poured into 1400 ml of tert.butyl-methyl ether. The precipitate is filtered off under N_2 , washed with a little of tert.butyl-methyl ether and acetonitrile and dried. The hydrochloride of 6-amino-1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-aceto[2,1-b]furo[3,4-d][1,3]thiazin is obtained in the form of a white powder (HPLC content of more than 95%).

b) (6R-trans)-7-Amino-3-formyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid (7-amino-3-formyl-3-cephem-4-carboxylic acid)

2.64 g of the hydrochloride of 6-amino-1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-aceto[2,1-b]furo[3,4-d][1,3]thiazin are dissolved in 50 ml of methanol. To this solution a solution of 0.78 g of pyridin in 10 ml of methanol is added dropwise under ice cooling and stirring. The precipitate obtained is filtered off moisture free under nitrogen, washed with a little methanol and dried. (6R-trans)-7-Amino-3-formyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid is obtained in the form of a light brownish powder.

IR (KBr): 1799 cm^{-1} (8-lactam), 1672 cm^{-1} (CHO), 1606 and 1542 cm^{-1} (carboxylate)

UV-Spectrum: λ_{max} in H_2O = 302 nm.

c) N-(1,4,5a,6-Tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-aceto[2,1-b]furo[3,4-d][1,3]thiazin-6-yl)-2-(2-tritylaminothiazol-4-yl)-(Z)-2-methoxyiminoacetic acid amide

10 g of 7-amino-3-formyl-3-cephem-4-carboxylic acid in 200 ml of acetonitrile : methylenchloride (1:1) are treated with 37.4 ml of N,O-bis(trimethylsilyl)acetamide at room temperature within ca. 5 minutes. After ca. 30 minutes the reaction mixture is cooled to -10° and 21 g of 2-(2-tritylaminothiazol-4-yl)-(Z)-2-methoxyiminoacetic

acid chloride are added in 3 portions. The temperature raises to -5°. After ca. 45 minutes the reaction mixture is treated with 4 ml of water. The temperature raises to 20°. The reaction mixture is stirred for ca. 10 minutes and filtered. 15 g of active charcoal are added to this filtrate and stirring is continued for ca. 10 minutes. After filtration the solvent of the filtrate obtained is evaporated. The evaporation residue is treated with tert.butyl-methyl ether. A crystalline, almost colourless precipitate is obtained, filtered off and dried. Crystalline N-(1,4,5a,6-Tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]thiazin-6-yl)-2-(2-tritylaminothiazol-4-yl)-2-methoxyiminoacetic acid amide is obtained in form of a diastereomeric mixture in the ratio of ca. 1:1.

d) Trifluoroacetate of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]thiazin-6-yl)-2-(2-aminothiazol-4-yl)-(Z)-2-methoxyiminoacetic acid amide

5 g of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic acid amide are introduced into 20 ml of trifluoro acetic acid at 0°. The temperature raises to 10°. The reaction mixture is stirred for ca. 30 minutes at 0° and added dropwise into 200 ml of diethylether. The mixture obtained is stirred for ca. 5 minutes and filtered. A crystalline, diastereomeric mixture of the trifluoroacetate of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]thiazin-6-yl)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic acid amide in the ratio of ca. 1:1 is obtained.

Example B)

Trifluoroacetate of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetic acid amide

is obtained in form of a light yellow powder analogously as described in Example A) c) to d) but using in step c) 2-(2-tritylaminothiazol-4-yl)-(Z)-2-hydroxyimino acetic acid chloride instead of 2-(2-tritylaminothiazol-4-yl)-(Z)-2-methoxyimino-acetic acid chloride.

Example C)

Hydrochloride of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-2-(fluoromethoxyimino)acetic acid amide

A suspension of 3.73 g of 7-amino-3-formyl-3-cephem-4-carboxylic acid in a mixture of 80 ml of methylenchloride and 30 ml of acetonitrile is stirred at 0° with 16 ml of N,O-bis(trimethylsilyl)acetamide). Within ca.15 minutes a clear solution is obtained to which 3.9 g of (5-amino-1,2,4-thiadiazol-3-yl)-(Z)-2-fluormethoxyiminoacetic acid chloride, obtainable for example as described in Example 1 of EP-0 590 681, are added. The reaction mixture is stirred for ca. 1 hour at 0°. 500 ml of acetonitrile containing 10 g of water are added and the mixture is filtered to remove insolubles. The filtrate is evaporated. The residue is treated with 500 ml of acetonitrile, the mixture is filtered and the filtrate is evaporated. The solid obtained is treated with tert.butyl-methyl ether and dried. The hydrochloride of N-(1,4,5a,6-Tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-2-(fluoromethoxyimino)acetic acid amide is obtained in the form of a light brownish powder.

Example D)

Hydrochloride of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-(2-aminothiazol-4-yl)-(Z)-2-(acetoxyimino)acetic acid amide

40 g of 7-amino-3-formyl-3-cephem-4-carboxylic acid are suspended in 1500 ml of acetonitrile and cooled to 0°. Within ca. 20 minutes 170 ml of N,O-bis(trimethylsilyl)acetamide are added under stirring. Within ca.15 minutes at 0° a clear solution is obtained, which is cooled to -10° and to which 48 g of (2-aminothiazol-4-yl)-(Z)-2-(acetoxyimino)acetic acid chloride are added in portions in such a way that the temperature of the reaction mixture does not exceed - 8°. Stirring is continued for ca. 60 minutes at -10° and 168 ml of water are added. Stirring is continued for ca. further 20 minutes at 0° and for ca. 2 hours at room temperature. A crystalline precipitate forms, is filtered off, washed with ca. 350 ml of acetonitrile and ca. 100 ml of ether and dried. The hydrochloride of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-

-dioxo-3H,7H-azeto[2,1-b]furo-[3,4-d][1,3]-thiazin-6-yl)-2-(2-aminothiazol-4-yl)-(Z)-2-(acetoxylimino)acetic acid is obtained in form of a diastereomeric mixture in the ratio of ca. 1:1.

Example E)

Hydrochloride of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-(2-aminothiazol-4-yl)-(Z)-2-(hydroxyimino)acetic acid amide

10 g of the hydrochloride of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]thiazin-6-yl)-2-(2-aminothiazol-4-yl)-(Z)-2-(acetoxylimino)-acetic acid amide are suspended in 160 ml of acetonitrile and treated with 53 ml of water and 11 ml of 8 N HCl. The reaction mixture is stirred for ca. 14 hours at room temperature. A clear solution is obtained which is diluted with water-free acetonitrile to obtain the 3-fold volume. The solvent is evaporated off to obtain a volume of ca. 10 ml, which is treated with ca. 200 ml of acetonitrile. A precipitate forms which is treated with ether, filtered off and dried. The hydrochloride of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-(2-aminothiazol-4-yl)-(Z)-2-(hydroxyimino)acetic acid amide is obtained in yellowish coloured form.

Example F)

Trifluoroacetate of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-(2-aminothiazol-4-yl)-(Z)-2-[(1-carboxy-1-methylethoxy)imino]acetic acid amide

is obtained in form of a light brownish powder analogously as described in Example A) a) to c) but using 2-(2-tritylaminothiazol-4-yl)-(Z)-2-[(1-carboxy-1-methylethoxy)-imino]acetic acid chloride instead of 2-(2-tritylaminothiazol-4-yl)-(Z)-2-methoxyiminoacetic acid chloride.

Example G)

N-(1,4,5a,6-Tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-[2-(tert.-butoxycarbonylamino)thiazol-4-yl)-(Z)-2-pentenoic acid

amide

is obtained in form of a light brownish powder analogously as described in Example A) c) to d) but using 2-(2-(tert.butoxycarbonylamino)thiazol-4-yl)-(Z)-2-pentenoic acid chloride instead of 2-(2-tritylaminothiazol-4-yl)-(Z)-2-methoxyimino-acetic acid chloride.

Example H)**Dihydrochloride of 1-(hydrazinoiminomethyl)piperazine****a) Hydroiodide of 4-formyl-1-[imino(methylthio)methyl]piperazine**

25.5 g of 4-formyl-1-piperazinecarbothioamide are suspended in 80 ml of methanol, treated with 22 g of methyl iodide and refluxed. Within ca. 10 minutes a clear solution is obtained. The mixture is cooled to room temperature. The solvent is evaporated. Crystalline hydroiodide of 4-formyl-1-[imino(methylthio)methyl]piperazine is obtained.

b) Hydrochloride of 4-formyl-1-(hydrazinoiminomethyl)piperazine








48.1 g of the hydroiodide of 4-formyl-1-[imino(methylthio)methyl]piperazine are dissolved in 100 ml of water, run through a column filled with 800 ml of a strong basic ion exchanger in chloride form and eluted with 850 ml of water. The solvent is evaporated to obtain a volume of ca. 100 ml which is treated with 7.35 g of hydrazinehydrate. The reaction mixture is stirred for ca. 1 hour at room temperature and the solvent is evaporated off. The oily hydrochloride of 4-formyl-1-(hydrazinoiminomethyl)piperazine crystallizes on drying.

c) Dihydrochloride of 1-(hydrazinoiminomethyl)piperazine

11 g of the hydrochloride of 4-formyl-1-(hydrazinoiminomethyl)piperazine are dissolved in 400 ml of methanol and treated with 50 of $\text{HCl}_{\text{conc.}}$. The reaction mixture is stirred for ca. 14 hours at room temperature. A white precipitate forms, is filtered off, washed with methanol and ether, dried and recrystallized with water/ethanol. The dihydrochloride of 1-(hydrazinoiminomethyl)-piperazine is obtained in crystalline, colourless form.

Analogous in the manner as described in Example H) compounds of formula IV of TABLE 2 may be obtained:

TABLE 2

Ex.	R ₂	Salt	Process
I)		HCl	H) a) to c)
J)		HCl	H) a) to c)
K)		HCl	H) a) to c)
L)		2HCl	H) a) to c)
M)		2HCL	H) a) to c)
N)		HCl	H) a) to b)
O)		3HCl	H) c)

Example P)**1-Amino-3-(2-hydroxyethyl)-4-methylguanidine**

12.7 g of 2-methylamino-2-oxazoline are dissolved in 50 ml of water, treated with 3 g of hydrazinehydrate and stirred for ca. 17 hours at room temperature. The solvent is evaporated and 1-amino-3-(2-hydroxyethyl)-4-methylguanidine is obtained as oily residue crystallizing upon cooling.

Example Q)**Hydrochloride of 1,1-dimethyl-4-(hydrazinoiminomethyl)piperaziniumchloride****a) Hydroiodide of 1,1-dimethyl-4-[imino(methylthio)methyl]piperaziniumiodide**

3.2 g of 4-methyl-1-piperazinecarbothioamide are suspended in 100 ml of methanol. 6.2 g of methyl iodide are added and the mixture is refluxed for ca. 2 hours and cooled to 20° ab. The hydroiodide of 1,1-dimethyl-4-[imino(methylthio)methyl]piperaziniumiodide precipitates, is filtered off and dried.

b) Hydrochloride of 1,1-dimethyl-4-(hydrazinoiminomethyl)piperaziniumchloride

6.57 g of the hydroiodide of 1,1-dimethyl-4-[imino(methylthio)methyl]piperaziniumiodide are dissolved in 70 ml of water, run through a column filled with 150 ml of a strong basic ion exchanger in chloride form and eluted with 250 ml of water. Water is evaporated off the eluate to obtain to a volume of ca. 50 ml, which is treated with 0.9 ml of hydrazinehydrate and stirred overnight. The solvent is evaporated off and the residue obtained is treated with n-hexane. The hydrochloride of 1,1-dimethyl-4-(hydrazinoiminomethyl)piperaziniumchloride is obtained.

Example R)**Trihydrochloride of 1-[hydrazino(methylimino)methyl]piperazine****a) Hydrochloride of S-methyl-2-methylisothiosemicarbazide**

A solution of 239.8 g of the hydroiodide of S-Methyl-2-methylisothiosemicarbazide in 100 ml of water is run through a column filled with 1500 ml of a

strong basic ion exchanger in chloride form and eluted with water. The eluate is lyophilized and the lyophilization residue is treated with ether. The precipitate is filtered off and dried. The hydrochloride of S-methyl-2-methylisothiosemicarbazide is obtained as a white solid.

Melting point: 116 °

b) Hydrochloride of 4-formyl-1-[hydrazino(methylimino)methyl]piperazine

A mixture of 20 g of freshly distilled formylpiperazine and 27.3 g of the hydrochloride of S-methyl-2-methylisothiosemicarbazide in 250 ml of ethanol is refluxed overnight and the solvent is evaporated. The oily residue is dissolved in 70 ml of hot isopropanol and the solution is slowly cooled to 20°. A precipitate forms and the mixture is allowed to stand for ca. 2 hours at 4°. The hydrochloride of 4-formyl-1-[hydrazino(methylimino)methyl]piperazine is filtered off and recrystallized from isopropanol.





c) Trihydrochloride of 1-[hydrazino(methylimino)methyl]piperazine

10 g of the hydrochloride of 1-formyl-4-[hydrazino(methylimino)methyl]piperazine are dissolved in 250 ml of methanol. 50 ml of HCl_{conc.} are added, the mixture obtained is stirred overnight and the solvent is evaporated. A solid residue is obtained which is dried over solid KOH. The trihydrochloride of 1-[hydrazino(methylimino)methyl]piperazine is obtained in form of a white product.

In analogous manner as described in Example R) but reacting the hydrochloride of S-methyl-isothiosemicarbazide or the hydrochloride of S-methyl-2-methylisothiosemicarbazide or the hydrochloride of S-methyl-4-methylisothiosemicarbazide with a corresponding amine compounds of formula IV of TABLE 3 may be obtained.

TABLE 3

Ex.	R ₂	Salt
-----	----------------	------

S)		HCl
T)		HCl
U)		HCl
V)		2HCl

Example W)**Hydrochloride of 1-Amino-3-(3,4-dihydroxybenzylidenamino)guanidine**

1 g of the hydrochloride of diaminoguanidine are dissolved in 10 ml of 4 N HCl and diluted with 20 ml of methanol. This solution is treated quickly with a solution of 1 g of 3,4-dihydroxybenzaldehyde in 40 ml of methanol. The reaction mixture is stirred for some minutes at room temperature and the solvent is evaporated off. The residue is suspended in 50 ml of acetonitrile. The precipitate formed is filtered off and dried. The hydrochloride of 1-amino-3-(3,4-dihydroxybenzylidenamino)-guanidine is obtained.

Example X)**Hydroiodide of S-Methyl-4-cyclopropylthiosemicarbazide**

295 mg of 4-cyclopropylthiosemicarbazide are dissolved in 5 ml of dry methanol and treated with 154 ml of methyl iodide. The mixture is stirred at 40° under nitrogen for ca. 5 hours, cooled and treated with diethylether. A colourless precipitate of the

hydroiodide of S-Methyl-4-cyclopropylthiosemicarbazide is formed, filtered off, washed with diethylether and dried.

Example Y)

Hydroiodide of S-methyl-4-n-butylthiosemicarbazide

147 mg of 4-n-butylthiosemicarbazide in 2,5 ml of dry methanol are treated with 149 mg of methyl iodide. The mixture is stirred under nitrogen for ca. 5 hours, cooled and treated with diethylether. A colourless precipitate of the hydroiodide of S-methyl-4-n-butylthiosemicarbazide is formed, filtered off, washed with diethylether and dried.

Example Z)

1-Methyl-5-mercapto-1,2,4-triazol-3-carboxylic acid hydrazide

0.48 g of 1-methyl-5-mercapto-1,2,4-triazol-3-carboxylic acid methyl ester are dissolved in 10 ml of methanol, treated with 450 µl of hydrazinehydrate and stirred for ca. 2 hours at 20°. A precipitate of 1-methyl-5-mercapto-1,2,4-triazol-3-carboxylic acid hydrazide is formed, filtered off, washed with methanol and dried.

IR (KBr): 1669 cm⁻¹, 1608 cm⁻¹, 1517 cm⁻¹

¹³C-NMR (300 MHz, DMSO-d₆): 35.4 (NCH₃); 143.3, 154.3 and 166.7

Example AA)

Hydroiodide of 1,5-dimethyl-2-(hydrazinoiminomethyl)pyrrol

a) 1,5-Dimethylpyrrol-2-carbothioamide

5 g of 2-cyano-1,5-dimethylpyrrol are dissolved in 40 ml of ethanol and treated with 10 ml of triethylamine. 50 ml of an ethanolic H₂S solution (3.8 g/100 ml) are added and the mixture is heated for ca. 15 hours in an autoclave at 70°. The reaction mixture is cooled and the solvent is evaporated off to obtain ca. a quarter of its volume. 1,5-dimethylpyrrol-2-carbothioamide crystallizes upon cooling at 0° in the form of a light yellow precipitate.

b) Hydroiodide of 1,5-dimethyl-2-(imino(methylthio)methyl)pyrrol

1 g of 1,5-dimethylpyrrol-2-carbothioamide are dissolved in 20 ml of methanol

and treated with 1.7 g of methyl iodide. The reaction mixture is stirred for about 5 hours at room temperature. The solvent is evaporated until crystallization starts. The residue is cooled to ca. 0°. The crystalline hydroiodide of 1,5-dimethyl-2-[imino(methylthio)methyl]pyrrol is filtered off, washed with methanol and dried.

c) Hydroiodide of 1,5-dimethyl-2-(hydrazinoiminomethyl)pyrrol

1.3 g of the hydroiodide of 1,5-dimethyl-2-[imino(methylthio)methyl]pyrrol are dissolved in 20 ml of methanol. 0.28 g of hydrazinehydrate are added. The reaction mixture is stirred for ca. 3 hours, the solvent is evaporated off and the residue is recrystallized from acetonitrile/ether. The hydroiodide of 1,5-dimethyl-2-(hydrazinoiminomethyl)pyrrol is obtained.

Example AB)

Hydroiodide of 3,4-dihydroxy-2-(hydrazinoiminomethyl)benzene

is obtained in analogous manner as described in Example AA), but using 3,4-dihydroxy-thiobenzamide instead of 1,5-dimethylpyrrol-2-carbothioamide.

Example AC)

7-Amino-3-[[[(carboxymethoxy)imino]methyl]-3-cephem-4-carboxylic acid

A solution of 1.86 g of the hydrochloride of aminooxyacetic acid in 20 ml of water is treated under stirring at 0° with 3.16 g of the hydrochloride of 6-amino-1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]thiazin. The mixture is stirred for ca. 8 hours at 0°. 7-Amino-3-[[[(carboxymethoxy)imino]methyl]-3-cephem-4-carboxylic acid precipitates in form of colourless crystals, which are filtered off, washed with 5 ml of cold water and 5 ml of acetone and dried.

Example AD)

7-Amino-3-[(methoxyimino)methyl]-3-cephem-4-carboxylic acid

A solution of 0.5 g of the hydrochloride of O-methylhydroxylamine in 10 ml of water is treated under stirring at 0° with 1.38 g of 7-amino-3-formyl-3-cephem-4-carboxylic acid and stirred for ca. 8 hours at 0°. 7-Amino-3-[(methoxyimino)methyl]-3-cephem-4-carboxylic acid precipitates in form of almost white crystals, which are

filtered off, washed with 5 ml of cold water and 5 ml of acetone and dried.

Example AE)

7-Amino-3-[(hydroxyimino)methyl]-3-cephem-4-carboxylic acid

- a) A solution of 1.26 g of the hydrochloride of hydroxylamine in 7.5 ml of water is treated under stirring at 0° with 4.74 g of the hydrochloride of 6-amino-1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]thiazin and stirred for ca. 8 hours at 0° under nitrogen. The pH of the reaction mixture is adjusted to 3.5 using solid sodium hydrogen carbonate. 7-Amino-3-[(hydroxyimino)methyl]-3-cephem-4-carboxylic acid precipitates in form of colourless crystals, which are filtered off, washed with ca. 5 ml of cold water and 5 ml of acetone and dried.
- b) A suspension of 0.79 g of the hydrochloride of 6-amino-1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]thiazin in 10 ml of dichloromethane is treated under stirring at 4° with 2.67 g of N,O-bis-(trimethylsilyl)acetamide. A clear solution is obtained within 10 minutes. 0.21 g of the hydrochloride of hydroxylamine are added. The reaction mixture is stirred for ca. 2 hours under nitrogen at 4° and the solvent is evaporated off. The residue is treated with 10 ml of isopropylalcohol, precooled to 1°. 7-Amino-3-[(hydroxyimino)methyl]-3-cephem-4-carboxylic acid precipitates in form of almost colourless crystals which are filtered off, washed with 5 ml of acetone and dried.

Analogously as described in Examples AC) to AE) the compounds of Table 4 of formula VI may be obtained.

Table 4

Bsp:	R ₁	R ₂	Salz
------	----------------	----------------	------

AF)	H	$\text{—NH—C} \begin{array}{l} \text{=NH} \\ \text{NH}_2 \end{array}$	2HCl
AG)	H	—NH—CO—NH_2	2HCl
AH)	H	—NH—CS—NH_2	2HCl
AI)	H	$\text{—NH—C} \begin{array}{l} \text{=NH} \\ \text{S—CH}_3 \end{array}$	HCl
AJ)	H	$\text{—NH—C} \begin{array}{l} \text{=NH} \\ \text{NH—CH}_3 \end{array}$	2HCl
AK)	H	$\text{—NH—C}_6\text{H}_5$	$\text{H}_2\text{N—NH—C}_6\text{H}_5$

¹H-NMR-Spectra of the compounds obtained according to the Examples (Ex.)

Ex.	Spectrum
1	(300 MHz, CD ₃ OD): 8.43 (s, 1H, CH=N); 6.96 (s, 1H, CH); 5.99 (d, J=4.9 Hz, 1H, CH); 5.22 (d, J=4.9 Hz, 1 H, CH); 4.04 (s, 3H, OCH ₃); 3.99 and 3.56 (AB quartet, J=17.8 Hz, 2H, SCH ₂).
2	(90 MHz, DMSO-d ₆ + D ₂ O): 3.6 and 4.3 (AB quartet, J=18 Hz, 2H, SCH ₂); 5.3 (d, J=5.1 Hz, 1H, β-lactam-H); 5.95 (d, J=5.1 Hz, 1H, β-lactam-H); 6.95 (s, 1H, thiazolyl-H); 8.35 (s, 1H, CH=N).
3	(300 MHz, CD ₃ OD): 7.97 (s, 1H, CH=N); 6.84 (s, 1H, CH); 5.69 (d, J=4.9 Hz, 1H, CH); 5.13 (d, J=4.9 Hz, 1H, CH); 4.13 and 3.93 (AB quartet, J=16.8 Hz, 2H, SCH ₂); 3.81 (s, 3H, OCH ₃); 3.67 (s, 3H, OCH ₃).
4	(300 MHz, CD ₃ OD): 8.36 (s, 1H, CH=N); 6.87 (s, 1H, CH); 5.88 (d, J=4.9 Hz, 1H, CH); 5.29 (d, J=4.9 Hz, 1 H, CH); 4.00 (s, 3H, OCH ₃); 3.95 and 3.60 (AB quartet, J=17.8 Hz, 2H, SCH ₂).
5	(300 MHz, DMSO-d ₆): 3.57 and 4.43 (AB quartet, J=18.2 Hz, 2H, S-CH ₂); 4.71 (s, 2H, O-CH ₂); 5.30 (d, J=5.0 Hz, 1H, β-lactam-H); 5.91 (dd, J=5.0 and 7.9 Hz, 1H, β-lactam-H); 7.02 (s, 1H, CH thiazol); 7.9 (broad 4H, NH); 8.29 (s, 1H, CH=N); 9.88 (d, J=7.9 Hz, 1H, NH); 12.25 (s, 1H, OH).
6	(300 MHz, CD ₃ OD): 8.10 (s, 1H, CH=N); 7.01 (s, 1H, CH); 5.84 (d, J=4.9 Hz, 1H, CH); 5.29 (d, J=4.9 Hz, 1 H, CH); 3.98 (s, 3H, OCH ₃); 3.96 and 3.59 (AB quartet, J=16.8 Hz, 2H, SCH ₂).
7	(300 MHz, CD ₃ OD): 8.26 (s, 1H, CH=N); 7.04 (s, 1H, CH); 5.90 (d, J=5.1 Hz, 1H, CH); 5.24 (d, J=5.1 Hz, 1 H, CH); 4.05 (s, 3H, OCH ₃);

4.32 and 3.65 (AB quartet, $J=17.8$ Hz, 2H, SCH₂).

- 8 (300 MHz, CD₃OD): 8.46 (s, 1H, CH=N); 6.99 (s, 1H, CH); 5.95 (d, $J=5.2$ Hz, 1H, CH); 5.27 (d, $J=5.2$ Hz, 1 H, CH); 4.01 (s, 3H, OCH₃); 4.37 and 3.63 (AB quartet, $J=18.1$ Hz, 2H, SCH₂); 2.95 (s, 3H, N-CH₃).
- 9 (90 MHz, DMSO-d₆): 9.78 (d, $J=8.0$ Hz, 1H, CONH); 8.26 (s, 1H, CH=N); 6.91 (s, 1H, CH); 7.32 (dd, $J=7.3$ Hz, 2H, H_m); 7.05 (d, $J=7.3$ Hz, 2H, H_p); 6.78 (t, $J=7.3$ Hz, 1H, H_p); 5.76 (dd, $J_1=4.8$ Hz, $J_2=8.0$ Hz, 1H, CH); 5.25 (d, $J=4.8$ Hz, 1 H, CH); 3.91 (s, 3H, OCH₃); 4.16 and 3.76 (AB quartet, $J=17.4$ Hz, 2H, SCH₂).
- 10 (90 MHz, DMSO-d₆): 2.25 (s, 3H, CH₃CO); 3.65 and 4.55 (AB quartet, $J=18$ Hz, 2H, SCH₂); 5.4 (d, $J=5$ Hz, 1 H, β -lactam-H); 5.95 (dd, $J=5$ Hz and 8 Hz, 1H, β -lactam-H); 7.32 (s, 1H, thiazolyl-H); 8.4 (s, 1H, CH=N); 10.2 (d, $J=8.0$ Hz, 1H, NH).
- 11 (90 MHz, DMSO-d₆): 1.12 (t, $J=7.1$ Hz, 3H, CH₃); 3.29 (q, 2H, CH₂); 3.56 and 4.50 (AB quartet, $J=18.1$ Hz, 2H, SCH₂); 3.93 (s, 3H, N-O-CH₃); 5.30 (d, $J=5$ Hz, 1H, CH); 5.9 (q, $J=6$ Hz, and 8 Hz, 1H, CH); 6.90 (s, 1H, thiazolyl-H); 8.32 (s, 1H, CH=N); 9.86 (d, $J=8.0$ Hz, NH).
- 12 (90 MHz, DMSO-d₆): 1.85-2.15 (m, 4H); 3.25-3.7 (m, 5H, -CH₂-N-CH₂- and 1H of SCH₂); 4.0 (s, 3H, N-O-CH₃); 4.5 (part of the AB quartet, $J=18$ Hz, 1H of SCH₂); 5.3 (d, $J=5$ Hz, 1H, CH); 5.9 (q, $J=5$ Hz and 8 Hz, 1H, CH); 7.0 (s, 1H, thiazolyl-H); 8.8 (s, 1H, CH=N); 10.1 (d, $J=7.9$ Hz, NH).
- 13 (90 MHz, DMSO-d₆): 2.9 (broad s, 6H, N-CH₃, 3); 3.6 and 4.5 (AB quartet, $J=18$ Hz, 2H, SCH₂); 3.9 (s, 3H, N-O-CH₃); 5.3 (d, $J=5$ Hz, 1H, CH); (q, $J=5$ Hz and 8 Hz, 1H, CH); 6.95 (s, 1H, thiazolyl-H); 8.75 (s, 1H, CH=N); 9.95 (d, $J=8$ Hz, NH).

- 14 (90 MHz, DMSO- d_6): 3.65 (broad s, 4H, N-CH₂-CH₂-N); 3.5 and 4.4 (AB quartet, J=18Hz, 2H, SCH₂); 3.9 (s, 3H, N-O-CH₃); 5.3 (d, J=5.0Hz, 1H, CH); 5.85 (q, J=5Hz and 8Hz, 1H, CH); 6.9 (s, 1H, thiazolyl-H); 8.35 (s, 1H, CH=N); 9.9 (d, J=8Hz, NH).
- 15 (90 MHz, DMSO- d_6): 1.16 (t, J=7.1Hz, 3H, CH₃); 1.8-2 (m, 4H); 3.32 (q, 2H, CH₂); 3.45-3.65 (m, 5H, -CH₂-N-CH₂- and 1H of SCH₂); 3.91 (s, 3H, N-O-CH₃); 4.1 (part of the AB quartet, J=18Hz, 1H of SCH₂); 5.27 (d, J=5Hz, 1H, CH); 5.9 (q, J=5Hz and 8Hz, 1H, CH); 6.86 (s, 1H, thiazolyl-H); 8.56 (s, 1H, CH=N); 9.82 (d, J=8Hz, NH).
- 16 (90 MHz, DMSO- d_6): 2.86 (broad s, 3H, N-CH₃); 3.5 and 4.5 (AB quartet, J=18Hz, 2H, SCH₂); 5.3 (d, J=6Hz, 1H, CH); 5.9 (q, J=5Hz and 8Hz, 1H, CH); 6.85 (s, 1H, thiazolyl-H); 8.4 (s, 1H, CH=N); 9.8 (d, J=8Hz, NH).
- 17 (90 MHz, DMSO- d_6): 1.85-2.15 (m, 4H); 3.25-3.8 (m, 5H, -CH₂-N-CH₂- and 1H of SCH₂); 4.5 (part of the AB quartet, J=18Hz, 1H of SCH₂); 5.3 (d, J=5Hz, 1H, CH); 5.85 (q, J=5Hz and 8Hz, 1H, CH); 6.85 (s, 1H, thiazolyl-H); 8.7 (s, 1H, CH=N); 9.8 (d, J=7.9Hz, NH).
- 18 (90 MHz, DMSO- d_6): 2.86 (broad s, 6H, N-CH₃), 3); 3.55 and 4.47 (AB quartet, J=18.9Hz, 2H, SCH₂); 5.31 (d, J=5.1Hz, 1H, CH); 5.91 (q, J=5.1Hz and 7.9Hz, 1H, CH); 6.8 (s, 1H, thiazolyl-H); 8.58 (s, 1H, CH=N); 9.72 (d, J=7.9Hz, NH).
- 19 (90 MHz, DMSO- d_6): 3.7 (broad s, 4H, N-CH₂-CH₂-N); 3.55 and 4.35 (AB quartet, J=18.1Hz, 2H, SCH₂); 5.31 (d, J=5.0Hz, 1H, CH); 5.9 (q, J=5.1Hz and 8Hz, 1H, CH); 6.8 (s, 1H, thiazolyl-H); 8.38 (s, 1H, CH=N); 9.73 (d, J=8.0Hz, NH).
- 20 (300 MHz, CD₃OD): 8.34 (s, 1H, CH=N); 7.06 (s, 1H, CH); 5.93 (d,

J=4.9 Hz, 1H, CH); 5.32 (d, J=4.9 Hz, 1 H, CH); 4.09 (s, 3H, OCH₃); 4.33 and 3.64 (AB quartet, J=18.2 Hz, 2H, SCH₂).

- 21 (90 MHz, DMSO-d₆): 3.65 and 4.7 (AB quartet, J = 18 Hz, 2H, SCH₂); 3.95 (s, 3 H, O-CH₃); 4.2 (part of the AB quartet, J = 18 Hz, 1H of SCH₂); 5.3 (d, J = 5 Hz, 1 H, β-lactam-H); 5.85 (dd, J = 5 Hz and 8 Hz, β-lactam-H); 7.0 (s, 1 H, thiazolyl-H); 7 to 7.7 (m, 5 H, aromatic H); 8.45 (s, 1 H, CH=N); 9 (d, J = 8 Hz, NH).
- 22 (90 MHz, DMSO-d₆): 3.55 and 4.6 (AB quartet, J = 18 Hz, 2H, SCH₂); 3.93 (s, 3 H, O-CH₃); 4.2 (part of the AB quartet, J = 18 Hz, 1H of SCH₂); 5.3 (d, J = 5 Hz, 1 H, β-lactam-H); 5.85 (dd, J = 5 Hz and 8 Hz, β-lactam-H); 7.0 (s, 1 H, thiazolyl-H); 7 to 7.7 (m, 5 H, aromatic-H); 8.3 (s, 1 H, CH=N); 9.9 (d, J = 8 Hz, NH).
- 23 (90 MHz, DMSO-d₆): 3.05 (d, J = 4 Hz, 3 H, NHCH₃); 3.55 and 4.5 (AB quartet, J = 18 Hz, 2H, SCH₂); 3.93 (s, 3 H, O-CH₃); 4.2 (part of the AB quartet, J = 18 Hz, 1H of SCH₂); 5.25 (d, J = 5 Hz, 1 H, β-lactam-H); 5.8 (dd, J = 5 Hz and 8 Hz, β-lactam-H); 6.95 (s, 1 H, thiazolyl-H); 8.25 (s, 1 H, CH=N); 8.4 (d, J = 4 Hz, NHCH₃); 9.85 (d, J = 8 Hz, NH).
- 24 (90 MHz, DMSO-d₆): 2.85 (s, 3H, NCH₃); 3.1 to 3.7 (m, 9 H, 8 piperazinyl-H's and 1H of SCH₂); 3.95(s, 3 H, OCH₃); 4.1 (part of the AB quartet, J = 18 Hz, 1H of SCH₂); 3.95 (s, 3 H, O-CH₃); 5.3 (d, J = 5 Hz, 1 H, β-lactam-H); 5.85 (dd, J = 5 Hz and 8 Hz, β-lactam-H); 6.95 (s, 1 H, thiazolyl-H); 7.95 (s, 1 H, CH=N); 9.9 (d, J = 8 Hz, NH).
- 25 (90 MHz, DMSO-d₆): 3.6 and 4.55 (AB quartet, J = 18 Hz, 2H, SCH₂); 3.9 to 4.1 (m, 5 H, -OCH₃ and -N-CH₂-CH=CH₂); 5.1 to 5.5 (m, 3 H, β-lactam-H and -N-CH₂-CH=CH₂); 5.7 to 6.1 (m, 2H, β-lactam-H and N-CH₂-CH=CH₂); 6.95 (s, 1 H, thiazolyl-H); 8.3 (s, 1 H, CH=N); 9.95 (d, J = 8 Hz, NH).

- 26 (90 MHz, DMSO- d_6): 1.7 to 2 (m, 2 H, $-\text{CH}_2-\text{CH}_2-\text{CH}_3$); 3.1 to 3.5 (m, 4 H); 3.55 and 4.5 (AB quartet, $J = 18$ Hz, 2H, SCH_2); 3.95 (s, 3 H, O- CH_3); 5.3 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.95 (s, 1 H, thiazolyl-H); 8.3 (s, 1 H, $\text{CH}=\text{N}$); 9.9 (d, $J = 8$ Hz, NH).
- 27 (90 MHz, DMSO- d_6): 0.8 to 1.1 and 1.1 to 1.7 (m, 7 H, $-\text{CH}_2-\text{CH}_2-\text{CH}_3$); 3.15 to 3.45 (m, 2 H, $-\text{NHCH}_2-$); 3.6 and 4.55 (AB quartet, $J = 18$ Hz, 2H, SCH_2); 3.95 (s, 3 H, O- CH_3); 5.3 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.95 (s, 1 H, thiazolyl-H); 8.4 (s, 1 H, $\text{CH}=\text{N}$); 9.95 (d, $J = 8$ Hz, NH).
- 28 (90 MHz, DMSO- d_6): 3.05 (d, $J = 4$ Hz, 3 H, NHCH_3); 3.65 (s, 3 H, NCH_3); 3.55 and 4.6 (AB quartet, $J = 18$ Hz, 2H, SCH_2); 3.93 (s, 3 H, O- CH_3); 4.2 (part of the AB quartet, $J = 18$ Hz, 1H of SCH_2); 5.3 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 7.0 (s, 1 H, thiazolyl-H); 8.6 (s, 1 H, $\text{CH}=\text{N}$); 9.4 (d, $J = 8$ Hz, NH).
- 29 300 MHz, DMSO- d_6): 2.93 (d, $J = 4.6$ Hz, 3 H, NCH_3); 3.4 to 3.6 (m, 5H); 3.6 to 3.8 (m, 4H); 3.93 (s, 3 H, O- CH_3); 4.2 (part of the AB quartet, $J = 18$ Hz, 1H of SCH_2); 5.3 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.93 (s, 1 H, thiazolyl-H); 8.6 (s, 1 H, $\text{CH}=\text{N}$); 9.92 (d, $J = 8$ Hz, NH).
- 30 (90 MHz, DMSO- d_6): 1.3 (s, 9 H, $-\text{C}(\text{CH}_3)_3$); 3.55 and 4.55 (AB quartet, $J = 18$ Hz, 2H, SCH_2); 5.3 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.95 (s, 1 H, thiazolyl-H); 8.25 (s, 1 H, $\text{CH}=\text{N}$); 9.95 (d, $J = 8$ Hz, NH).
- 31 (90 MHz, DMSO- d_6): 2.9 (s, 3 H, NCH_3); 3.0 (s, 6 H, $\text{N}(\text{CH}_3)_2$); 3.6 and 4.2 (AB quartet, $J = 18$ Hz, 2H, SCH_2); 3.95 (s, 3 H, O- CH_3); 5.3 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 7.0 (s,

1 H, thiazolyl-H); 8.55 (s, 1 H, CH=N); 9.95 (d, J = 8 Hz, NH).

- 32 (90 MHz, DMSO- d_6) : 2.85 (s, 2 H); 3.55 and 4.6 (AB quartet, J = 18 Hz, 2H, SCH₂); 3.95 (s, 3 H, O-CH₃); 5.3 (d, J = 5 Hz, 1 H, β -lactam-H); 5.85 (dd, J = 5 Hz and 8 Hz, β -lactam-H); 6.95 (s, 1 H, thiazolyl-H); 8.65 (s, 1 H, CH=N); 9.9 (d, J = 8 Hz, NH).
- 33 (90 MHz, DMSO- d_6): 3.4 to 3.8 (m, 9 H, morpholino H's and 1H of SCH₂); 3.95 (s, 3 H, O-CH₃); 4.6 (part of the AB quartet, J = 18 Hz, 1H of SCH₂); 5.3 (d, J = 5 Hz, 1 H, β -lactam-H); 5.85 (dd, J = 5 Hz and 8 Hz, β -lactam-H); 6.95 (s, 1 H, thiazolyl-H); 8.7 (s, 1 H, CH=N); 9.9 (d, J = 8 Hz, NH).
- 34 (300 MHz, DMSO- d_6): 3.32 (s, 9H, -N⁺(CH₃)₃); 0.4 to 1 (m, 4 H, -CH₂-CH₂-); 2.5 to 2.8 (m, 1 H); 3.65 and 4.17 (AB quartet, J = 18.1 Hz, 2H, SCH₂); 3.94 (s, 3 H, O-CH₃); 4.8 (q, J = 17 Hz, 2H); 5.3 (d, J = 5 Hz, 1 H, β -lactam-H); 5.85 (dd, J = 5 Hz and 8 Hz, β -lactam-H); 6.94 (s, 1 H, thiazolyl-H); 8.26 (s, 1 H, CH=N); 9.93 (d, J = 8 Hz, NH).
- 35 (90 MHz, DMSO- d_6): 0.4 to 1 (m, 4 H, -CH₂-CH₂-); 2.5 to 2.8 (m, 1 H), 3.55 and 4.6 (AB quartet, J = 18 Hz, 2H, SCH₂); 3.95 (s, 3 H, O-CH₃); 5.3 (d, J = 5 Hz, 1 H, β -lactam-H); 5.85 (dd, J = 5 Hz and 8 Hz, β -lactam-H); 6.9 (s, 1 H, thiazolyl-H); 8.35 (s, 1 H, CH=N); 9.85 (d, J = 8 Hz, NH).
- 36 (90 MHz, DMSO- d_6): 3.6 and 4.55 (AB quartet, J = 18 Hz, 2H, SCH₂); 3.95 s, 3 H, O-CH₃); 5.3 (d, J = 5 Hz, 1 H, β -lactam-H); 5.85 (dd, J = 5 Hz and 8 Hz, β -lactam-H); 6.9 (s, 1 H, thiazolyl-H); 8.5 (s, 1 H, CH=N); 9.85 (d, J = 8 Hz, NH); 10.4 (broad singlet, 1 H, -NH-OH).
- 37 (90 MHz, DMSO- d_6): 3.1 (s, 3 H, N-CH₃); 3.55 and 4.6 (AB quartet, J = 18 Hz, 2H, SCH₂); 3.9 (s, 3 H, O-CH₃); 5.3 (d, J = 5 Hz, 1 H, β -lactam-

H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.9 (s, 1 H, thiazolyl-H); 8.7 (s, 1 H, CH=N); 9.85 (d, $J = 8$ Hz, NH).

- 38 (300 MHz, DMSO- d_6): 3.56 and 4.54 (AB quartet, $J = 18.1$ Hz, 2H, SCH₂); 3.91 (s, 3 H, O-CH₃); 4.87 (d, $J = 6.5$ Hz, 2 H); 5.3 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.89 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.88 (s, 1 H, thiazolyl-H); 7.6 (m, 2 H, pyridinyl-H); 8.15 (m, 1 H, pyridinyl-H); 8.39 (s, 1 H, CH=N); 8.86 (m, 1 H, pyridinyl-H); 9.83 (d, $J = 8$ Hz, NH).
- 39 (300 MHz, DMSO- d_6): 3.57 and 4.52 (AB quartet, $J = 18.1$ Hz, 2H, SCH₂); 3.91 (s, 3 H, O-CH₃); 4.87 (d, $J = 6$ Hz, 2 H); 5.3 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.89 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.88 (s, 1 H, thiazolyl-H); 8.15 (m, 1 H, pyridinyl-H); 8.38 (s, 1 H, CH=N); 8.45 (m, 1 H, pyridinyl-H); 8.8 (m, 1 H, pyridinyl-H); 8.85 (s, 1 H, pyridinyl-H); 9.91 (d, $J = 8$ Hz, NH).
- 40 (300 MHz, DMSO- d_6): 3.58 and 4.57 (AB quartet, $J = 18.3$ Hz, 2H, SCH₂); 3.9 (s, 3 H, O-CH₃); 5.06 (broad singulet, 2 H); 5.3 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.88 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.94 (s, 1 H, thiazolyl-H); 8.02 (d, $J = 6.6$ Hz, 2 H, pyridinyl-H); 8.4 (s, 1 H, CH=N); 8.92 (d, $J = 6.6$ Hz, 2 H, pyridinyl-H); 9.91 (d, $J = 8$ Hz, NH).
- 41 (90 MHz, DMSO- d_6): 3.65 and 4.35 (AB quartet, $J = 18$ Hz, 2H, SCH₂); 3.9 (s, 3 H, O-CH₃); 4.2 (d, $J = 7$ Hz, 2H); 5.2 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.75 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.95 (s, 1 H, thiazolyl-H); 7.85 (s, 1 H, CH=N); 9.8 (d, $J = 8$ Hz, NH).
- 42 (90 MHz, DMSO- d_6): 2.95 (broad duplet, 3 H, N-CH₃); 3.0 to 3.3 (m, 4 H, -CH₂-N-CH₂); 3.4 to 3.8 (m, 5 H, -CH₂-NH⁺-CH₂- and 1H of SCH₂); 3.85 (s, 3 H, O-CH₃); 4.1 (part of the AB quartet, $J = 18$ Hz, 1H of SCH₂); 5.25 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.8 (s, 1 H, thiazolyl-H); 8.65 (s, 1 H, CH=N); 9.75 (d, $J =$

8 Hz, NH).

- 43 (90 MHz, DMSO- d_6): 3.7 and 4.85 (AB quartet, $J = 18$ Hz, 2H, SCH₂); 3.95 (s, 3 H, O-CH₃); 5.35 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.95 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 7.0 (s, 1 H, thiazolyl-H); 7.2 (t, $J = 6$ Hz, 1 H, pyridinyl-H); 7.4 (d, $J = 8$ Hz, 1 H, pyridinyl-H); 8.15 (t, $J = 6$ Hz, 2 H, pyridinyl-H); 8.55 (s, 1 H, CH=N); 9.95 (d, $J = 8$ Hz, NH).
- 44 (90 MHz, DMSO- d_6): 3.6 and 4.05 (AB quartet, $J = 18$ Hz, 2H, SCH₂); 3.95 (s, 3 H, O-CH₃); 5.25 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.75 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.9 (s, 1 H, thiazolyl-H); 8.5 (s, 1 H, CH=N); 9.85 (d, $J = 8$ Hz, NH).
- 45 (300 MHz, DMSO- d_6): 1.4 to 1.7 (m, 6 H); 3.4 to 3.7 (m, 5 H, -CH₂-N-CH₂- and 1H of SCH₂); 3.92 (s, 3 H, O-CH₃); 4.55 (part of the AB quartet, $J = 18$ Hz, 1H of SCH₂); 5.29 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.89 (dd, $J = 5$ Hz and 7.8 Hz, β -lactam-H); 6.89 (s, 1 H, thiazolyl-H); 8.6 (s, 1 H, CH=N); 9.84 (d, $J = 7.8$ Hz, NH).
- 46 (90 MHz, DMSO- d_6): 3.1 to 3.4 (m, 4 H, -CH₂-NH⁺-CH₂-); 3.65 and 4.65 (AB quartet, $J = 18$ Hz, 2H, SCH₂); 3.85 (s, 3 H, O-CH₃); 4 to 4.3 (m, 4 H, -CH₂-N-CH₂-); 4.65 (part of the AB quartet, $J = 18$ Hz, 1H of SCH₂); 5.2 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.8 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.75 (s, 1 H, thiazolyl-H); 8.5 (s, 1 H, CH=N); 9.7 (d, $J = 8$ Hz, NH).
- 47 (300 MHz, DMSO- d_6): 2.85 (broad singlet, 3 H, N-CH₃); 3.54 and 4.52 (AB quartet, $J = 18.1$ Hz, 2H, SCH₂); 3.93 (s, 3 H, O-CH₃); 5.3 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.89 (dd, $J = 5$ Hz and 7.9 Hz, β -lactam-H); 6.91 (s, 1 H, thiazolyl-H); 8.62 (s, 1 H, CH=N); 9.88 (d, $J = 7.9$ Hz, NH); 12.0 (s, 1 H, OH).

- 48 (90 MHz, DMSO- d_6): 3.2 (s, 6 H, NCH_3); 3.7 (s, 4 H, $-N-(CH_2)_2-N-$); 3.65 and 4.0 (AB quartet, $J = 17.8$ Hz, 2H, SCH_2); 3.95 (s, 3 H, $O-CH_3$); 5.3 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.95 (s, 1 H, thiazolyl-H); 8.8 (s, 1 H, $CH=N$); 9.9 (d, $J = 8$ Hz, NH).
- 49 (300 MHz, DMSO- d_6): 3.7 and 4.13 (AB quartet, $J = 17.8$ Hz, 2H, SCH_2); 3.9 (s, 3 H, $O-CH_3$); 5.31 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.89 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.92 (s, 1 H, thiazolyl-H); 8.13 (d, $J = 6$ Hz, 2 H, pyridinyl-H); 8.7 (s, 1 H, $CH=N$); 8.93 (m, 3 H, pyridinyl-H); 9.88 (d, $J = 8$ Hz, NH).
- 50 (300 MHz, DMSO- d_6): 2.94 (d, $J = 4.7$ Hz, 3 H, $N-CH_3$); 3.29 (broad s, 6 H, $N^*(CH_2)_2$); 3.3 to 3.7 (m, 9H, piperazinyl-H's and 1H of SCH_2); 3.93 (s, 3 H, $O-CH_3$); 4.2 (part of the AB quartet, $J = 18$ Hz, 1H of SCH_2); 5.28 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.89 (dd, $J = 5$ Hz and 7.6 Hz, β -lactam-H); 6.9 (s, 1 H, thiazolyl-H); 8.1 (s, 1 H, formyl-H); 8.6 (s, 1 H, $CH=N$); 9.9 (d, $J = 8$ Hz, NH).
- 51 (300 MHz, DMSO- d_6): 3.7 and 4.2 (AB quartet, $J = 18$ Hz, 2H, SCH_2); 3.93 (s, 3 H, $O-CH_3$); 5.35 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.0 (AB quartet, $J = 9$ Hz, 2H); 6.93 (s, 1 H, thiazolyl-H); 8.2 (t, $J = 7$ Hz, 2 H), 8.7 (t, $J = 7$ Hz, 1 H) and 9.1 (d, $J = 6$ Hz, 2H), pyridinium-H; 8.32 (s, 1 H, $CH=N$); 9.95 (d, $J = 8$ Hz, NH).
- 52 (90 MHz, DMSO- d_6): 3.7 (s, 3 H, $N-CH_3$); 3.65 and 4.1 (AB quartet, $J = 18$ Hz, 2H, SCH_2); 3.95 (s, 3 H, $O-CH_3$); 5.35 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 7.0 (s, 1 H, thiazolyl-H); 8.75 (s, 1 H, $CH=N$); 9.9 (d, $J = 8$ Hz, NH).
- 53 (90 MHz, DMSO- d_6): 2.25 (s, 3 H, triazinyl- CH_3); 3.5 and 4.65 (AB quartet, $J = 18$ Hz, 2H, SCH_2); 4.0 (s, 3 H, $O-CH_3$); 5.35 (d, $J = 5$ Hz, 1

H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.95 (s, 1 H, thiazolyl-H); 8.85 (s, 1 H, CH=N); 9.95 (d, $J = 8$ Hz, NH).

54 (90 MHz, DMSO- d_6): 2.3 (s, 3 H, CH₃); 1.8 to 2.1 (m, 1 H); 3.6 and 4.55 (AB quartet, $J = 18$ Hz, 2H, SCH₂); 3.95 (s, 3 H, O-CH₃); 5.35 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.9 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.95 (s, 1 H, thiazolyl-H); 8.65 (s, 1 H, CH=N); 9.9 (d, $J = 8$ Hz, NH).

55 (90 MHz, DMSO- d_6): 2.8 (broad duplet, 3H, N-CH₃); 3.2 to 3.7 (m, 5 H, N-CH₂-CH₂-O and 1H of SCH₂); 3.95 (s, 3 H, O-CH₃); 4.5 (part of the AB quartet, $J = 18$ Hz, 1H of SCH₂); 5.3 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.95 (s, 1 H, thiazolyl-H); 8.65 (s, 1 H, CH=N); 9.9 (d, $J = 8$ Hz, NH).

56 (90 MHz, DMSO- d_6): 3.7 and 4.15 (AB quartet, $J = 18$ Hz, 2H, SCH₂); 4.0 (s, 3 H, O-CH₃); 5.35 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 7.0 (s, 1 H, thiazolyl-H); 7 to 7.8 (m, 4 H, aromatic-H); 8.45 (s, 1 H, CH=N); 9.95 (d, $J = 8$ Hz, NH).

57 (90 MHz, DMSO- d_6): 3.35 broad singulet, 3 H, NCH₃); 3.55 and 4.55 (AB quartet, $J = 18$ Hz, 2H, SCH₂); 3.95 (s, 3 H, O-CH₃); 5.3 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.95 (s, 1 H, thiazolyl-H); 8.15 (s, 1 H, CH=N); 9.85 (d, $J = 8$ Hz, NH).

58 (90 MHz, DMSO- d_6): 2.95 (broad duplet, 3 H, NCH₃); 3.35 (broad singulet, 3 H, NCH₃); 3.65 and 4.65 (AB quartet, $J = 18$ Hz, 2H, SCH₂); 3.95 (s, 3 H, O-CH₃); 5.3 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.95 (s, 1 H, thiazolyl-H); 8.1 (s, 1 H, CH=N); 9.85 (d, $J = 8$ Hz, NH).

59 (90 MHz, DMSO- d_6): 1 to 1.5 (m, 4 H, -CH₂-CH₂-); 1.8 to 2.1 (m, 1 H); 3.55 and 4.55 (AB quartet, $J = 18$ Hz, 2H, SCH₂); 3.95 (s, 3 H, O-CH₃);

5.3 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.9 (s, 1 H, thiazolyl-H); 8.65 (s, 1 H, CH=N); 9.9 (d, $J = 8$ Hz, NH).

60 (90 MHz, DMSO- d_6): 3.7 and 4.8 (AB quartet, $J = 18$ Hz, 2H, SCH₂); 4.0 (s, 3 H, O-CH₃); 5.35 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.95 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 7.0 (s, 1 H, thiazolyl-H); 7.85 (dd, $J = 4$ Hz and 6 Hz, pyridinyl-H); 8.2 (dt, $J = 2$ and 8 Hz, pyridinyl-H); 8.5 (d, $J = 6$ Hz, pyridinyl-H); 8.9 (d, $J = 4$ Hz, pyridinyl-H); 8.95 (s, 1 H, CH=N); 9.95 (d, $J = 8$ Hz, NH).

61 (90 MHz, DMSO- d_6): 3.6 and 4.15 (AB quartet, $J = 18$ Hz, 2H, SCH₂); 3.85 (s, 3 H, O-CH₃); 5.25 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.75 (s, 1 H, thiazolyl-H); 7.5 (dd, $J = 5$ Hz and 8 Hz, pyridinyl-H); 8.25 (broad duplet, $J = 8$ Hz, pyridinyl-H); 8.65 (broad triplet, $J = 6$ Hz, pyridinyl-H); 9.05 (s, 1 H, CH=N); 9.7 (d, $J = 8$ Hz, NH).

62 (300 MHz, DMSO- d_6): 3.13 (broad duplet, 3 H, N-CH₃); 3.29 (broad s, 6 H, N⁺(CH₃)₂); 3.4 to 3.75 (m, 5 H, -CH₂-N⁺-CH₂- and 1H of SCH₂); 3.85 (s, 3 H, O-CH₃); 4 to 4.3 (m, 4 H, -CH₂-N-CH₂-); 4.65 (part of the AB quartet, $J = 18$ Hz, 1H of SCH₂); 5.27 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 7.6 Hz, β -lactam-H); 6.78 (s, 1 H, thiazolyl-H); 8.75 (s, 1 H, CH=N); 9.75 (d, $J = 7.6$ Hz, NH).

63 (90 MHz, DMSO- d_6 +TFA): 3.0 (broad duplet, 3 H, N-CH₃); 3.2 (s, 9 H, N⁺(CH₃)₂); 3.5 to 3.8 (m, 5 H, N-CH₂-CH₂-N⁺ and 1H of SCH₂); 3.90 (s, 3 H, O-CH₃); 4.65 (part of the AB quartet, $J = 18$ Hz, 1H of SCH₂); 5.3 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.8 (s, 1 H, thiazolyl-H); 8.75 (s, 1 H, CH=N); 9.75 (d, $J = 8$ Hz, NH).

- 64 (90 MHz, DMSO- d_6): 3.65 and 4.15 (AB quartet, $J = 18$ Hz, 2H, SCH₂); 4.0 (s, 3 H, O-CH₃); 5.25 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.8 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 7.0 (s, 1 H, thiazolyl-H); 7.2 (d, $J = 5$ Hz, 1 H, pyrimidinyl-H); 8.45 (s, 1 H, CH=N); 8.8 (d, $J = 5$ Hz, 1 H, pyrimidinyl-H); 9.9 (d, $J = 8$ Hz, NH).
- 65 (90 MHz, DMSO- d_6 +TFA): 4.0 (s, 3 H, O-CH₃); 3.6 and 4.65 (AB quartet, $J = 18$ Hz, 2H, SCH₂); 5.25 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 7.0 (s, 1 H, thiazolyl-H); 8.3 (s, 1 H, CH=N); 9.85 (d, $J = 8$ Hz, NH).
- 66 (90 MHz, DMSO- d_6): 3.2 (broad singlet, 3 H, N-CH₃); 3.0 to 3.4 (m, 4 H, -CH₂-N-CH₂); 3.4 to 3.8 (m, 5 H, -CH₂-NH⁺-CH₂- and 1H of SCH₂); 3.95 (s, 3 H, O-CH₃); 4.3 (part of the AB quartet, $J = 18$ Hz, 1H of SCH₂); 5.35 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 7.0 (s, 1 H, thiazolyl-H); 8.15 (s, 1 H, CH=N); 9.9 (d, $J = 8$ Hz, NH).
- 67 (90 MHz, DMSO- d_6): 3.3 (s, 3 H, N-CH₃); 3.3 (broad s, 6 H, N⁺(CH₃)₂); 3.3 to 3.7 (m, 9H, piperazinyl-H's and 1H of SCH₂); 3.85 (s, 3 H, O-CH₃); 4.25 (part of the AB quartet, $J = 18$ Hz, 1H of SCH₂); 5.25 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.8 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.8 (s, 1 H, thiazolyl-H); 8.1 (s, 1 H, formyl-H); 8.15 (s, 1 H, CH=N); 9.75 (d, $J = 8$ Hz, NH).
- 68 (90 MHz, DMSO- d_6): 2.25 (s, 3 H); 3.65 (s, 3 H, N-CH₃); 3.7 and 4.6 (AB quartet, $J = 18$ Hz, 2H, SCH₂); 3.9 (s, 3 H, O-CH₃); 5.3 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.05 (d, $J = 4$ Hz, pyrrol-H); 6.85 (d, $J = 4$ Hz, pyrrol-H); 6.9 (s, 1 H, thiazolyl-H); 8.75 (s, 1 H, CH=N); 9.9 (d, $J = 8$ Hz, NH).
- 69 (90 MHz, DMSO- d_6): 3.5 and 4.45 (AB quartet, $J = 20$ Hz, 2H, SCH₂);

5.25 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.75 (d, $J = 55$ Hz, 2H, $-\text{CH}_2\text{F}$); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 8.25 (s, 1 H, $\text{CH}=\text{N}$); 9.85 (d, $J = 8$ Hz, NH).

- 70 (300 MHz, $\text{DMSO}-d_6$): 1.13 (t, $J=7.1$ Hz, 3H, CH_3); 3.31 (qd, $J=7.1$ and ca. 6 Hz, 2H, CH_2); 3.55 and 4.47 (AB quartet, $J=18.1$ Hz, 2H, $\text{S}-\text{CH}_2$); 5.29 (d, $J=5.0$ Hz, 1H, β -lactam-H); 5.89 (dd, $J=5.0$ and 7.9 Hz, 1H, β -lactam-H); 6.78 (s, 1H, CH thiazol); 8.01 (broad, 2H, NH); 8.19 (broad t 1H, NH) ; 8.32 (s, 1H, $\text{CH}=\text{N}$); 9.70 (d, $J=7.9$ Hz, 1H, NH); 12.03 (s, 1H, OH).
- 71 (300 MHz, $\text{DMSO}-d_6$): 2.98 (d, $J=4.6$ Hz, 3H, $\text{N}-\text{CH}_3$); 3.56 and 4.46 (AB quartet, $J=18.1$ Hz, 2H, $\text{S}-\text{CH}_2$); 5.28 (d, $J=4.9$ Hz, 1H, β -lactam-H); 5.87 (dd, $J=4.9$ and 7.9 Hz, 1H, β -lactam-H); 6.83 (s, 1H, CH thiazol); 8.22 (s, 1H, $\text{CH}=\text{N}$); 8.48 (q broad $J=4.6$ Hz, 1H, NH); 9.75 (d, $J=7.9$ Hz, 1H, NH); 11.63 (s, 1H, OH); 12.28 (s, 1H, OH).
- 72 (300 MHz, $\text{DMSO}-d_6$): 3.53 and 4.47 (AB quartet, $J=18.1$ Hz, 2H, $\text{S}-\text{CH}_2$); 5.26 (d, $J=5.0$ Hz, 1H, β -lactam-H); 5.88 (dd, $J=4.9$ and 7.9 Hz, 1H, β -lactam-H); 6.84 (s, 1H, CH thiazol); 8.00 (s, 1H, NH); 8.23 (s, 1H, $\text{CH}=\text{N}$); 8.28 (s, 1H, NH); 9.76 (d, $J=7.9$ Hz, 1H, NH); 11.56 (s, 1H, OH); 12.31 (s, 1H, OH).
- 73 (300 MHz, $\text{DMSO}-d_6$): 1.16 (t, $J=7.1$ Hz, 3H, CH_3); 1.90 (m broad, 4H, CH_2); 3.39 (qd, $J=7.1$ and ca. 6 Hz, 2H, CH_2); 3.56 (m broad, 4H, CH_2); 3.63 and 4.07 (AB quartet, $J=18.0$ Hz, 2H, $\text{S}-\text{CH}_2$); 5.28 (d, $J=5.0$ Hz, 1H, β -lactam-H); 5.88 (dd, $J=5.0$ and 7.8 Hz, 1H, β -lactam-H); 6.81 (s, 1H, CH thiazol); 7.97 (t broad, $J=$ ca. 6 Hz 1H, NH); 8.60 (s, 1H, $\text{CH}=\text{N}$); 9.76 (d, $J=7.8$ Hz, 1H, NH); 11.70 (s, 1H, OH); 12.26 (s, 1H, OH).
- 74 (300 MHz, $\text{DMSO}-d_6$): 3.57 and 4.48 (AB quartet, $J=18.1$ Hz, 2H,

S-CH₂); 3.97 (broad, 2H, N-CH₂-C=C); 5.1-5.3 (m, 2H, C=CH₂); 5.30 (d, J=5.1 Hz, 1H, β-lactam-H); 5.8-5.9 (m, 1H, C-CH=C); 5.89 (dd, J=4.9 and 8.2 Hz, 1H, β-lactam-H); 6.83 (s, 1H, CH thiazol); 8.10 (s, 2H, NH); 8.34 (s, 1H, CH=N); 8.41 (s, 1H, NH); 9.77 (d, J=8.0 Hz, 1H, NH); 12.26 (s, 1H, OH); 12.38 (s, 1H, OH).

- 75 (300 MHz, DMSO-d₆): 1.89 (m broad 2H, CH₂); 3.33 (s broad, 4H, N-CH₂); 3.54 and 4.42 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 5.29 (d, J=5.0 Hz, 1H, β-lactam-H); 5.89 (dd, J=5.0 and 8.0 Hz, 1H, β-lactam-H); 6.76 (s, 1H, CH thiazol); 8.29 (s, 1H, CH=N); 8.38 (s, 2H, NH); 9.66 (d, J=8.0 Hz, 1H, NH); 11.90 (s, 1H, OH); 12.03 (s, 1H, OH).
- 76 (300 MHz, DMSO-d₆): 0.89 (t, 3H, C-CH₃); 1.2-1.4 (m, 2H, C-CH₂-C); 1.4-1.6 (m, 2H, C-CH₂-C); 3.2-3.4 (m, 2H, N-CH₂-C); 3.56 and 4.47 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 5.30 (d, J=5.0 Hz, 1H, β-lactam-H); 5.89 (dd, J=5.0 and 7.9 Hz, 1H, β-lactam-H); 6.83 (s, 1H, CH thiazol); 8.04 (s, 2H, NH); 8.24 (s, 1H, CH=N); 8.32 (s, 1H, NH); 9.76 (d, J=7.9 Hz, 1H, NH); 12.13 (s, 1H, OH); 12.36 (s, 1H, OH).
- 77 (300 MHz, DMSO-d₆): 3.66 and 3.92 (AB quartet, J=17.9 Hz, 2H, S-CH₂); 3.86 (s, 3H, O-CH₃); 5.27 (d, J=5.0 Hz, 1H, β-lactam-H); 5.88 (dd, J=5.0 and 7.8 Hz, 1H, β-lactam-H); 6.84 (s, 1H, CH thiazol); 8.22 (s, 1H, CH=N); 9.78 (d, J=7.8 Hz, 1H, NH); 12.34 (s, 1H, OH).
- 78 (300 MHz, DMSO-d₆): 1.39 (s, 9H, C-CH₃); 3.56 and 4.47 (AB quartet, J=18.0 Hz, 2H, S-CH₂); 5.29 (d, J=5.0 Hz, 1H, β-lactam-H); 5.89 (dd, J=5.0 and 7.9 Hz, 1H, β-lactam-H); 6.81 (s, 1H, CH thiazol); 7.90 (s broad 2H, NH); 7.99 (s broad 1H, NH); 8.25 (s, 1H, CH=N); 9.68 (d, J=7.9 Hz, 1H, NH); 12.03 (s, 1H, OH); 12.16 (s, 1H, OH).
- 79 (300 MHz, DMSO-d₆): 2.92 (d, J=4.8 Hz, 3H, N-CH₃); 3.03 (s, 6H, N-CH₃); 3.61 and 4.17 (AB quartet, J=18.0 Hz, 2H, S-CH₂); 5.29 (d,

J=5.0 Hz, 1H, β -lactam-H); 5.88 (dd, J=5.0 and 7.8 Hz, 1H, β -lactam-H); 6.81 (s, 1H, CH thiazol); 8.20 (q broad J=4.8 Hz, 1H, NH); 8.55 (s, 1H, CH=N); 9.76 (d, J=7.5 Hz, 1H, NH); 11.83 (s, 1H, OH); 12.28 (s, 1H, OH).

80 (300 MHz, DMSO- d_6): 2.75 (s, 2H, N-CH₂); 3.55 and 4.54 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 5.32 (d, J=5.1 Hz, 1H, β -lactam-H); 5.93 (dd, J=5.1 and 7.9 Hz, 1H, β -lactam-H); 6.79 (s, 1H, CH thiazol); 8.59 (s, 1H, CH=N); 9.73 (d, J=8.0 Hz, 1H, NH); 12.13 (s, 1H, OH).

81 (300 MHz, DMSO- d_6): 3.55 and 4.54 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 3.5-3.6 (m, 4H, CH₂); 3.6-3.7 (m, 4H, CH₂); 5.30 (d, J=5.1 Hz, 1H, β -lactam-H); 5.89 (dd, J=5.0 and 7.9 Hz, 1H, β -lactam-H); 6.84 (s, 1H, CH thiazol); 8.35 (broad, 2H, NH); 8.65 (s, 1H, CH=N); 9.80 (d, J=7.9 Hz, 1H, NH); 12.27 (s, 1H, OH); 12.51 (s, 1H, OH).

82 (300 MHz, DMSO- d_6): 0.64 (m, 2H, cyclopr. CH₂); 0.83 (m, 2H, cyclopr. CH₂); 2.62 (m, 1H, cyclopr. CH); 3.53 and 4.49 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 5.29 (d, J=5.0 Hz, 1H, β -lactam-H); 5.89 (dd, J=5.0 and 8.0 Hz, 1H, β -lactam-H); 6.79 (s, 1H, CH thiazol); 8.09 (s, 2H, NH); 8.35 (s, 1H, CH=N); 8.59 (s, 1H, NH); 9.70 (d, J=8.0 Hz, 1H, NH); 12.08 (s, 1H, OH); 12.13 (s, 1H, OH).

83 (300 MHz, DMSO- d_6): 3.54 and 4.48 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 5.29 (d, J=5.0 Hz, 1H, β -lactam-H); 5.89 (dd, J=4.9 and 7.8 Hz, 1H, β -lactam-H); 6.83 (s, 1H, CH thiazol); 8.15 (s, 2H, NH); 8.39 (s, 1H, CH=N); 9.79 (d, J=7.9 Hz, 1H, NH); 11.21 (s, 1H, OH); 12.15 (s, 1H, OH); 12.44 (s, 1H, OH).

84 (300 MHz, DMSO- d_6): 3.09 (s, 6H, N-CH₃); 3.55 and 4.55 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 5.30 (d, J=5.0 Hz, 1H, β -lactam-H); 5.89 (dd, J=5.0 and 7.8 Hz, 1H, β -lactam-H); 6.84 (s, 1H, CH thiazol); 8.07 (s, 2H,

NH); 8.65 (s, 1H, CH=N); 9.81 (d, J=7.9 Hz, 1H, NH); 11.86 (s, 1H, OH); 12.53 (s, 1H, OH).

- 85 (300 MHz, DMSO- d_6): 3.58 and 4.50 (AB quartet, J=18.0 Hz, 2H, S-CH₂); 4.90 (d, J=6.4 Hz, 2H, N-CH₂); 5.31 (d, J=5.1 Hz, 1H, β -lactam-H); 5.90 (dd, J=5.2 and 7.8 Hz, 1H, β -lactam-H); 6.84 (s, 1H, CH thiazol); 7.6-7.8 (m, 2H, CH aromatic); 8.1-8.3 (m, 1H, CH aromatic); 8.35 (s broad, 1H, NH); 8.39 (s, 1H, CH=N); 8.7-8.8 (m, 2H, CH aromatic); 9.3 (broad, 1H, NH); 9.78 (d, J=7.8 Hz, 1H, NH); 12.42 (s, 1H, OH); 12.49 (s, 1H, OH).
- 86 (300 MHz, DMSO- d_6): 3.57 and 4.52 (AB quartet, J=18.0 Hz, 2H, S-CH₂); 4.85 (d, J=6.6 Hz, 2H, N-CH₂); 5.30 (d, J=5.0 Hz, 1H, β -lactam-H); 5.90 (dd, J=5.0 and 7.8 Hz, 1H, β -lactam-H); 6.82 (s, 1H, CH thiazol); 7.9-8.1 (m, 1H, CH aromatic); 8.38 (s, 1H, CH=N); 8.4-8.6 (m, 1H, CH aromatic); 8.8-8.9 (m, 1H, CH aromatic); 8.9-9.0 (m, 1H, CH aromatic); 8.7-8.8 (m, 2H, CH aromatic); 9.77 (d, J=7.9 Hz, 1H, NH); 12.32 (s, 1H, OH); 12.45 (s, 1H, OH).
- 87 (300 MHz, DMSO- d_6): 3.57 and 4.52 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 4.98 (d, J=6.2 Hz, 2H, N-CH₂); 5.30 (d, J=5.0 Hz, 1H, β -lactam-H); 5.90 (dd, J=5.0 and 7.9 Hz, 1H, β -lactam-H); 6.81 (s, 1H, CH thiazol); 7.9-8.0 (m, 2H, CH aromatic); 8.40 (s, 1H, CH=N); 8.8-9.0 (m, 1H, CH aromatic); 9.00 (s broad 1H, NH); 9.76 (d, J=7.9 Hz, 1H, NH); 12.30 (s, 1H, OH); 12.56 (s, 1H, OH).
- 88 (300 MHz, DMSO- d_6): 3.68 and 4.05 (AB quartet, J=17.9 Hz, 2H, S-CH₂); 4.19 and 4.38 (AB quartet, J=16.4 Hz, 2H, N-CH₂-C=O); 5.30 (d, J=5.0 Hz, 1H, β -lactam-H); 5.87 (dd, J=5.0 and 7.7 Hz, 1H, β -lactam-H); 6.87 (s, 1H, CH thiazol); 7.86 (s, 1H, CH=N); 9.82 (d, J=7.7 Hz, 1H, NH); 11.35 (s, 1H, OH); 12.45 (s, 1H, OH).

- 89 (300 MHz, DMSO- d_6): 3.58 and 4.64 (AB quartet, $J=18.1$ Hz, 2H, S-CH₂); 5.29 (d, $J=4.9$ Hz, 1H, β -lactam-H); 5.89 (dd, $J=4.9$ and 7.9 Hz, 1H, β -lactam-H); 6.84 (s, 1H, CH thiazol); 7.1-7.6 (m, CH aromatic); 8.33 (s, 1H, CH=N); 9.78 (d, $J=7.9$ Hz, 1H, NH); 10.03 (s, 1H, NH); 11.86 (s, 1H, OH); 12.35 (s, 1H, OH).
- 90 (300 MHz, DMSO- d_6): 3.66 and 4.70 (AB quartet, $J=18.1$ Hz, 2H, S-CH₂); 5.34 (d, $J=5.0$ Hz, 1H, β -lactam-H); 5.92 (dd, $J=5.0$ and 7.9 Hz, 1H, β -lactam-H); 6.84 (s, 1H, CH thiazol); 7.0-7.2 (m, 1H, CH aromatic); 7.2-7.3 (m, 1H, CH aromatic); 8.0-8.2 (m, 2H, CH aromatic); 8.49 (s, 1H, CH=N); 9.79 (d, $J=8.0$ Hz, 1H, NH); 12.32 (s, 1H, OH); 13.41 (s, 1H, OH).
- 91 (300 MHz, DMSO- d_6): 3.65 and 4.03 (AB quartet, $J=17.8$ Hz, 2H, S-CH₂); 5.27 (d, $J=4.9$ Hz, 1H, β -lactam-H); 5.83 (dd, $J=4.9$ and 7.7 Hz, 1H, β -lactam-H); 6.88 (s, 1H, CH thiazol); 8.52 (s, 1H, CH=N); 9.77 (d, $J=7.7$ Hz, 1H, NH); 11.08 (s, 1H, OH); 12.35 (s, 1H, OH).
- 92 (300 MHz, DMSO- d_6): 1.51 (s, 3H, C-CH₃); 1.54 (s, 3H, C-CH₃); 2.86 (d, $J=4.9$ Hz, 3H, N-CH₃); 3.55 and 4.50 (AB quartet, $J=18.2$ Hz, 2H, S-CH₂); 5.32 (d, $J=5.1$ Hz, 1H, β -lactam-H); 5.96 (dd, $J=5.0$ and 8.2 Hz, 1H, β -lactam-H); 6.95 (s, 1H, CH thiazol); 8.03 (s broad 2H, NH); 8.18 (s broad 1H, NH); 8.32 (s, 1H, CH=N); 9.74 (d, $J=7.9$ Hz, 1H, NH); 12.19 (s, 1H, OH).
- 93 (300 MHz, DMSO- d_6): 2.9 (broad, 3H, N-CH₃); 3.54 and 4.50 (AB quartet, $J=18.1$ Hz, 2H, S-CH₂); 5.30 (d, $J=5.1$ Hz, 1H, β -lactam-H); 5.89 (dd, $J=5.0$ and 7.8 Hz, 1H, β -lactam-H); 6.83 (s, 1H, CH thiazol); 8.62 (s, 1H, CH=N); 9.79 (d, $J=7.9$ Hz, 1H, NH); 11.98 (s, 1H, OH); 12.42 (s, 1H, OH).
- 94 (300 MHz, DMSO- d_6): 3.39 (m broad 2H, CH₂); 3.54 (m broad 2H, CH₂);

2.89 (d, $J=4.6$ Hz, 3H, N-CH₃); 3.55 and 4.49 (AB quartet, $J=18.0$ Hz, 2H, S-CH₂); 5.30 (d, $J=5.0$ Hz, 1H, β -lactam-H); 5.90 (dd, $J=5.0$ and 7.9 Hz, 1H, β -lactam-H); 6.79 (s, 1H, CH thiazol); 8.61 (s, 1H, CH=N); 9.71 (d, $J=7.9$ Hz, 1H, NH); 11.73 (s, 1H, OH); 12.10 (s, 1H, OH).

95 (300 MHz, DMSO-d₆): 2.26 (s, 3H, CH₃); 3.57 and 4.70 (AB quartet, $J=18.0$ Hz, 2H, S-CH₂); 5.33 (d, $J=5.0$ Hz, 1H, β -lactam-H); 5.93 (dd, $J=5.0$ and 7.9 Hz, 1H, β -lactam-H); 6.83 (s, 1H, CH thiazol); 8.77 (s, 1H, CH=N); 9.80 (d, $J=7.9$ Hz, 1H, NH); 12.40 (s, 1H, OH).

96 (300 MHz, DMSO-d₆): 3.22 (m broad 4H, N-CH₂); 3.55 and 4.52 (AB quartet, $J=18.1$ Hz, 2H, S-CH₂); 3.85 (m broad 4H, N-CH₂); 5.30 (d, $J=5.0$ Hz, 1H, β -lactam-H); 5.90 (dd, $J=5.0$ and 7.9 Hz, 1H, β -lactam-H); 6.82 (s, 1H, CH thiazol); 8.5 (broad, 2H, NH); 8.65 (s, 1H, CH=N); 9.76 (d, $J=7.9$ Hz, 1H, NH); 9.82 (s, 2H, NH); 12.31 (s, 1H, OH); 12.47 (s, 1H, OH).

97 (300 MHz, DMSO-d₆): 3.14 (s, 6H, N-CH₃); 3.64 and 3.94 (AB quartet, $J=17.9$ Hz, 2H, S-CH₂); 3.68 (s 4H, N-CH₂); 5.28 (d, $J=5.0$ Hz, 1H, β -lactam-H); 5.89 (dd, $J=5.0$ and 7.7 Hz, 1H, β -lactam-H); 6.81 (s, 1H, CH thiazol); 8.64 (s, 1H, CH=N); 9.77 (d, $J=7.7$ Hz, 1H, NH); 12.29 (s, 1H, OH); 12.36 (s, 1H, OH).

98 (300 MHz, DMSO-d₆): 3.33 (s, 3H, N-CH₃); 3.54 and 4.55 (AB quartet, $J=18.3$ Hz, 2H, S-CH₂); 5.29 (d, $J=5.0$ Hz, 1H, β -lactam-H); 5.91 (dd, $J=5.1$ and 7.9 Hz, 1H, β -lactam-H); 6.76 (s, 1H, CH thiazol); 8.10 (s, 1H, CH=N); 8.2 (s, NH); 9.67 (d, $J=7.8$ Hz, 1H, NH); 11.92 (s, 1H, OH).

99 (300 MHz, DMSO-d₆): 2.80 (s, 3H, CH₃); 3.57 and 4.48 (AB quartet, $J=18.1$ Hz, 2H, S-CH₂); 5.34 (d, $J=5.1$ Hz, 1H, β -lactam-H); 5.94 (dd, $J=5.1$ and 7.9 Hz, 1H, β -lactam-H); 6.82 (s, 1H, CH thiazol); 8.55 (s, 1H, CH=N); 9.28 (s, 1H, NH); 9.80 (d, $J=7.9$ Hz, 1H, NH); 9.90 (s, 1H, NH);

12.39 (s, 1H, OH); 13.52 (s, 1H, OH).

100 (300 MHz, DMSO- d_6): 3.58 and 4.46 (AB quartet, $J=18.1$ Hz, 2H, S-CH₂); 5.34 (d, $J=5.1$ Hz, 1H, β -lactam-H); 5.94 (dd, $J=5.1$ and 7.9 Hz, 1H, β -lactam-H); 6.82 (s, 1H, CH thiazol); 8.28 (dd, $J=6.7$ and 14.8 Hz, 1H, N-CH=N); 8.58 (s, 1H, CH=N); 9.58 (d, $J=14.8$ Hz 1H, NH); 9.77 (d, $J=8.0$ Hz, 1H, NH); 9.9 (d, $J=6.7$ Hz 1H, NH); 12.29 (s, 1H, OH).

101 (300 MHz, DMSO- d_6): 3.57 and 4.48 (AB quartet, $J=18.0$ Hz, 2H, S-CH₂); 3.9 (s, 3H, O-CH₃); 5.33 (d, $J=5.1$ Hz, 1H, β -lactam-H); 5.92 (dd, $J=5.1$ and 8.0 Hz, 1H, β -lactam-H); 6.87 (s, 1H, CH thiazol); 8.27 (dd, $J=6.9$ and 14.6 Hz, 1H, N-CH=N); 8.60 (s, 1H, CH=N); 9.55 (d, $J=14.4$ Hz 1H, NH); 9.79 (d, $J=8.0$ Hz, 1H, NH); 9.91 (d, $J=6.5$ Hz 1H, NH).

102 (300 MHz, DMSO- d_6): 1.49 (s, 3H, C-CH₃); 1.50 (s, 3H, C-CH₃); 3.54 and 4.48 (AB quartet, $J=18.1$ Hz, 2H, S-CH₂); 5.31 (d, $J=4.9$ Hz, 1H, β -lactam-H); 5.97 (dd, $J=4.9$ and 8 Hz, 1H, β -lactam-H); 6.84 (s, 1H, CH thiazol); 8.29 (s, 1H, CH=N); 9.65 (d, $J=8$ Hz, 1H, NH); 12.06 (s, 1H, OH).

103 (300 MHz, DMSO- d_6): 1.51 (s, 3H, C-CH₃); 1.53 (s, 3H, C-CH₃); 3.52 and 4.52 (AB quartet, $J=18.3$ Hz, 2H, S-CH₂); 5.30 (d, $J=5.0$ Hz, 1H, β -lactam-H); 5.95 (dd, $J=5.0$ and 8.1 Hz, 1H, β -lactam-H); 6.94 (s, 1H, CH thiazol); 7.61 (s broad 2H, NH); 8.15 (s broad 2H, NH); 8.38 (s, 1H, CH=N); 9.74 (d, $J=8.1$ Hz, 1H, NH); 11.20 (s, 1H, OH); 12.16 (s, 1H, OH).

104 (300 MHz, DMSO- d_6): 1.49 (s, 3H, C-CH₃); 1.51 (s, 3H, C-CH₃); 3.56 and 4.52 (AB quartet, $J=18.3$ Hz, 2H, S-CH₂); 4.90 (d, $J=6.3$ Hz, 2H, CH₂); 5.32 (d, $J=5.0$ Hz, 1H, β -lactam-H); 5.97 (dd, $J=5.0$ and 8.1 Hz, 1H, β -lactam-H); 6.91 (s, 1H, CH thiazol); 7.6-7.8 (m 2H, CH aromatic);

8.2-8.3 (m 1H, CH aromatic); 8.38 (s, 1H, CH=N); 8.6-8.8 (m 1H, CH aromatic); 9.71 (d, J=8.2 Hz, 1H, NH); 12.48 (s, 1H, OH).

105 (300 MHz, DMSO-d₆): 0.64 (m broad 2H, CH₂); 0.84 (m broad 2H, CH₂); 1.50 (s, 3H, C-CH₃); 1.52 (s, 3H, C-CH₃); 2.61 (m broad 1H, N-CH); 3.53 and 4.53 (AB quartet, J=18.2 Hz, 2H, S-CH₂); 5.31 (d, J=5.0 Hz, 1H, β-lactam-H); 5.96 (dd, J=5.0 and 8.2 Hz, 1H, β-lactam-H); 6.90 (s, 1H, CH thiazol); 8.10 (s broad 2H, NH); 8.34 (s, 1H, CH=N); 8.60 (s broad 1H, NH); 9.70 (d, J=8.2 Hz, 1H, NH); 12.08 (s, 1H, OH).

106 (300 MHz, DMSO-d₆): 1.50 (s, 3H, C-CH₃); 1.52 (s, 3H, C-CH₃); 2.87 (broad 6H, N-CH₃); 3.54 and 4.51 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 5.33 (d, J=5.0 Hz, 1H, β-lactam-H); 5.96 (dd, J=5.0 and 8.1 Hz, 1H, β-lactam-H); 6.91 (s, 1H, CH thiazol); 8.06 (s broad 1H, NH); 8.30 (s broad 1H, NH); 8.62 (s, 1H, CH=N); 9.71 (d, J=8.4 Hz, 1H, NH); 11.76 (s, 1H, OH).

107 (300 MHz, DMSO-d₆): 1.51 (s, 3H, C-CH₃); 1.53 (s, 3H, C-CH₃); 1.8-2.0 (m, 4H, C-CH₂); 1.8-2.0 (m, 4H, N-CH₂); 3.54 and 4.55 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 5.31 (d, J=5.0 Hz, 1H, β-lactam-H); 5.95 (dd, J=5.0 and 8.3 Hz, 1H, β-lactam-H); 6.90 (s, 1H, CH thiazol); 7.70 (s broad NH); 7.93 (s broad NH); 8.63 (s, 1H, CH=N); 9.62 (d, J=8.2 Hz, 1H, NH); 9.75 (s, 1H, NH); 11.71 (s, 1H, OH).

108 (300 MHz, CD₃OD): 8.59 (s, 1H, CH=N); 6.94 (s, 1H, CH); 5.95 (d, J=5.0 Hz, 1H, CH); 5.29 (d, J=5.0 Hz, 1 H, CH); 4.02 (s, 3H, OCH₃); 4.34 and 3.61 (AB quartet, J=18.0 Hz, 2H, SCH₂); 2.73 (s, 3H, SCH₃).

109 (300 MHz, DMSO-d₆): 0.64 (m broad 2H, CH₂ cyclopr); 0.84 (m broad 2H, CH₂ cyclopr); 2.62 (m broad 1H, N-CH cyclopr); 3.54 and 4.51 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 4.66 (s, 2H, O-CH₂); 5.30 (d, J=5.0 Hz, 1H, β-lactam-H); 5.93 (dd, J=5.0 and 8.1 Hz, 1H, β-lactam-H); 6.93 (s,

1H, CH thiazol); 8.09 (broad 2H, NH); 8.35 (s, 1H, CH=N); 8.58 (broad, 1H, NH); 9.77 (d, J=8.0 Hz, 1H, NH); 12.04 (s, 1H, OH).

- 110 (300 MHz, DMSO-d₆): 2.87 (s, 6H, N-CH₃); 3.56 and 4.50 (AB quartet, J=18.0 Hz, 2H, S-CH₂); 4.67 (s, 2H, O-CH₂); 5.32 (d, J=5.0 Hz, 1H, β-lactam-H); 5.92 (dd, J=5.0 and 8.1 Hz, 1H, β-lactam-H); 6.94 (s, 1H, CH thiazol); 8.1 (broad 1H, NH); 8.35 (broad 1H, NH); 8.63 (s, 1H, CH=N); 9.80 (d, J=8.1 Hz, 1H, NH); 11.77 (s, 1H, OH).
- 111 (300 MHz, DMSO-d₆): 1.93 (broad, 4H, C-CH₂); 3.47 (broad, 4H, N-CH₂); 3.55 and 4.54 (AB quartet, J=17.9 Hz, 2H, S-CH₂); 4.67 (s, 2H, O-CH₂); 5.30 (d, J=5.0 Hz, 1H, β-lactam-H); 5.92 (dd, J=5.0 and 7.9 Hz, 1H, β-lactam-H); 6.94 (s, 1H, CH thiazol); 7.96 (broad 2H, NH); 8.62 (s, 1H, CH=N); 9.79 (d, J=7.8 Hz, 1H, NH); 11.72 (s, 1H, OH).
- 112 (300 MHz, DMSO-d₆): 3.62 and 4.67 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 5.37 (d, J=5.1 Hz, 1H, β-lactam-H); 5.96 (dd, J=5.1 and 7.9 Hz, 1H, β-lactam-H); 6.83 (s, 1H, CH thiazol); 7.7-7.9 (m, 1H, CH aromatic); 8.1-8.3 (m, 1H, CH aromatic); 8.4-8.6 (m, 1H, CH aromatic); 8.8-8.9 (m, 1H, CH aromatic); 8.97 (s, 1H, CH=N); 9.79 (d, J=7.9 Hz, 1H, NH); 9.85 (s, 1H, NH); 10.37 (s, 1H, NH); 12.31 (s, 1H, OH).
- 113 (300 MHz, DMSO-d₆): 1.1-1.3 (m, 2H, CH₂ cyclopr); 1.2-1.4 (m, 2H, CH₂ cyclopr); 1.9-2.0 (m, 1H, CH₂ cyclopr); 3.54 and 4.49 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 5.32 (d, J=5.1 Hz, 1H, β-lactam-H); 5.93 (dd, J=5.1 and 8.0 Hz, 1H, β-lactam-H); 6.76 (s, 1H, CH thiazol); 8.59 (s, 1H, CH=N); 9.07 (s, 1H, NH); 9.23 (s, 1H, NH); 9.67 (d, J=8.0 Hz, 1H, NH); 11.92 (s, 1H, OH); 13.27 (s, 1H, OH).
- 114 (300 MHz, DMSO-d₆): 1.59 (broad, 6H, C-CH₂); 3.53 (broad 4H, N-CH₂); 3.6 and 4.52 (AB quartet, J=18.4 Hz, 2H, S-CH₂); 5.29 (d, J=5.0 Hz, 1H, β-lactam-H); 5.89 (dd, J=5.0 and 7.6 Hz, 1H, β-lactam-H); 6.82 (s, 1H,

CH thiazol); 8.16 (s 2H, NH); 8.60 (s, 1H, CH=N); 9.75 (d, J=7.6 Hz, 1H, NH); 11.94 (s, 1H, OH); 12.30 (s, 1H, OH).

- 115 (300 MHz, DMSO- d_6): 3.5 and 4.53 (AB quartet, J=17.9 Hz, 2H, S-CH₂); 3.4-3.7 (m, 8H, N-CH₂); 5.31 (d, J=5.0 Hz, 1H, β -lactam-H); 5.90 (dd, J=5.0 and 7.9 Hz, 1H, β -lactam-H); 6.82 (s, 1H, CH thiazol); 8.08 (s, 1H, CH=O); 8.38 (broad 2H, NH); 8.62 (s, 1H, CH=N); 9.75 (d, J=7.9 Hz, 1H, NH); 12.18 (s, 1H, OH); 12.28 (s, 1H, OH).
- 116 (300 MHz, DMSO- d_6 /D₂O): 2.81 (s, 6H, N-CH₃); 2.92 (s, 3H, C=N-CH₃); 3.54 and 4.58 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 3.6 (broad, 2H, N-CH₂); 3.97 (broad, 2H, N-CH₂); 5.30 (d, J=4.8 Hz, 1H, β -lactam-H); 5.90 (d, J=4.8 Hz, 1H, β -lactam-H); 6.81 (s, 1H, CH thiazol); 8.55 (s, 1H, CH=N).
- 117 (300 MHz, DMSO- d_6 /D₂O): 2.91 (s, 3H, C=N-CH₃); 3.19 (s, 9H, N-CH₃); 3.29 (broad, 2H, N-CH₂); 3.56 and 4.48 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 3.82 (broad, 2H, N-CH₂); 5.31 (d, J=5.0 Hz, 1H, β -lactam-H); 5.90 (d, J=5.0 Hz, 1H, β -lactam-H); 6.84 (s, 1H, CH thiazol); 8.56 (s, 1H, CH=N).
- 118 (300 MHz, DMSO- d_6): 3.61 and 4.59 (AB quartet, J=18.0 Hz, 2H, S-CH₂); 5.35 (d, J=5.1 Hz, 1H, β -lactam-H); 5.59 (dd, J=5.1 and 7.9 Hz, 1H, β -lactam-H); 6.82 (s, 1H, CH thiazol); 6.9-7.1 (m, 1H, CH aromatic); 7.2-7.4 (m, 2H, CH aromatic); 8.74 (s, 1H, CH=N); 9.31 (s 1H, NH/OH); 9.76 (s 1H, NH/OH); 9.78 (d, J=7.9 Hz, 1H, NH); 12.25 (s, 1H, OH); 13.03 (s, 1H, OH).
- 119 (300 MHz, DMSO- d_6): 2.30 (s, 3H, C-CH₃); 3.59 and 4.57 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 3.67 (s, 3H, N-CH₃); 5.34 (d, J=5.1 Hz, 1H, β -lactam-H); 5.94 (dd, J=5.1 and 8.0 Hz, 1H, β -lactam-H); 6.13 (d,

- J=3.9 Hz 1H, CH Pyrrol); 6.77 (s, 1H, CH thiazol); 6.86 (d, J=3.9 Hz 1H, CH Pyrrol); 8.66 (s, 1H, CH=N); 9.25 (s 1H, NH); 9.46 (s 1H, NH); 9.70 (d, J=8.0 Hz, 1H, NH); 11.96 (s, 1H, OH); 12.90 (s, 1H, OH).
- 120 (300 MHz, DMSO-d₆): 3.71 and 4.12 (AB quartet, J=17.9 Hz, 2H, S-CH₂); 5.32 (d, J=5.1 Hz, 1H, β-lactam-H); 5.91 (dd, J=5.0 and 7.9 Hz, 1H, β-lactam-H); 6.84 (s, 1H, CH thiazol); 7.9-8.0 (m, 2H, CH aromatic); 8.66 (s, 1H, CH=N); 8.8-8.9 (m, 2H, CH aromatic); 8.8 (broad 1H, NH); 9.76 (d, J=8.0 Hz, 1H, NH); 12.17 (s, 1H, OH); 12.37 (s, 1H, OH).
- 121 (300 MHz, DMSO-d₆): 3.22 (s, 6H, N-CH₃); 3.54 and 4.55 (AB quartet, J=18.5 Hz, 2H, S-CH₂); 3.6 (broad, 4H, N-CH₂); 4.0 (broad, 4H, N-CH₂); 5.30 (d, J=5.0 Hz, 1H, β-lactam-H); 5.91 (dd, J=5.0 and 7.9 Hz, 1H, β-lactam-H); 6.82 (s, 1H, CH thiazol); 8.73 (s, 1H, CH=N); 9.75 (d, J=7.6 Hz, 1H, NH); 12.30 (s, 1H, OH); 12.76 (s, 1H, OH).
- 122 (300 MHz, DMSO-d₆): 2.76 (s, 3H, N-CH₃); 3.1-3.3 (broad, 2H, N-CH₂); 3.4-3.6 (broad, 2H, N-CH₂); 3.5-3.7 (broad, 2H, N-CH₂); 3.55 and 4.53 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 4.2-4.4 (broad, 2H, N-CH₂); 5.31 (d, J=5.0 Hz, 1H, β-lactam-H); 5.90 (dd, J=5.0 and 7.8 Hz, 1H, β-lactam-H); 6.82 (s, 1H, CH thiazol); 8.66 (s, 1H, CH=N); 9.77 (d, J=7.8 Hz, 1H, NH); 11.74 (s, 1H, NH); 12.36 (s, 1H, OH); 12.56 (s, 1H, OH).
- 123 (300 MHz, DMSO-d₆): 2.90 (d, J=4.7 Hz 3H, N-CH₃); 3.34 (s, 3H, N-CH₃); 3.55 and 4.59 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 5.30 (d, J=5.0 Hz, 1H, β-lactam-H); 5.91 (dd, J=5.0 and 7.9 Hz, 1H, β-lactam-H); 6.81 (s, 1H, CH thiazol); 8.09 (s, 1H, CH=N); 8.25 (s, 2H, NH); 8.37 (s, 1H, NH); 9.72 (d, J=7.9 Hz, 1H, NH); 12.14 (s, 1H, OH).
- 124 (300 MHz, DMSO-d₆): 2.81 (d, J=4.3 Hz 6H, N-CH₃); 3.2-3.4 (m broad 2H, N-CH₂); 3.56 and 4.55 (AB quartet, J=18.0 Hz, 2H, S-CH₂); 3.7-3.9 (m broad 2H, N-CH₂); 5.30 (d, J=4.9 Hz, 1H, β-lactam-H); 5.9 (dd, J=4.9

and 7.9 Hz, 1H, β -lactam-H); 6.82 (s, 1H, CH thiazol); 8.3 (broad, NH); 8.38 (s, 1H, CH=N); 8.47 (broad, NH); 9.76 (d, J=7.9 Hz, 1H, NH); 10.84 (s, 1H, NH); 12.31 (s, 2H, OH).

- 125 (300 MHz, DMSO- d_6): 2.82 (d, J=4.5 Hz 6H, N-CH₃); 3.2-3.3 (m broad 2H, N-CH₂); 3.40 (s, 3H, N-CH₃); 3.56 and 4.73 (AB quartet, J=18.3 Hz, 2H, S-CH₂); 3.8-3.9 (m broad 2H, N-CH₂); 5.29 (d, J=5.0 Hz, 1H, β -lactam-H); 5.91 (dd, J=5.0 and 7.8 Hz, 1H, β -lactam-H); 6.82 (s, 1H, CH thiazol); 8.11 (s, 1H, CH=N); 8.68 (s, 2H, NH); 8.74 (m broad 1H, NH); 9.77 (d, J=7.9 Hz, 1H, NH); 10.91 (s, 1H, OH); 12.32 (s, 1H, OH).
- 126 (300 MHz, DMSO- d_6): 3.60 and 4.56 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 5.32 (d, J=5.0 Hz, 1H, β -lactam-H); 5.92 (dd, J=5.0 and 7.9 Hz, 1H, β -lactam-H); 6.83 (s, 1H, CH thiazol); 6.8-6.9 (m, 1H, CH aromatic); 7.1-7.2 (m, 1H, CH aromatic); 7.3-7.4 (m, 1H, CH aromatic); 8.23 (s, 1H, CH=N); 8.37 (2H, NH/OH); 8.51 (s, 1H, CH=N); 9.78 (d, J=7.9 Hz, 1H, NH); 12.27 (s, 1H, OH).
- 127 (300 MHz, DMSO- d_6): 3.53 and 4.49 (AB quartet, J=18.1 Hz, 2H, S-CH₂); 5.29 (d, J=5.0 Hz, 1H, β -lactam-H); 5.89 (dd, J=5.0 and 7.9 Hz, 1H, β -lactam-H); 6.79 (s, 1H, CH thiazol); 7.93 (broad, 2H, NH); 8.37 (broad, 1H, CH=N); 9.73 (d, J=7.8 Hz, 1H, NH); 12.15 (s, 1H, OH).
- 128 (300 MHz, DMSO- d_6): 3.25 (broad, 4H, N-CH₂); 3.31 (s, 3H, N-CH₃); 3.62 and 4.27 (AB quartet, J=18.0 Hz, 2H, S-CH₂); 3.74 (broad, 4H, N-CH₂); 5.30 (d, J=5.0 Hz, 1H, β -lactam-H); 5.89 (dd, J=4.9 and 7.9 Hz, 1H, β -lactam-H); 6.79 (s, 1H, CH thiazol); 8.11 (s, 1H, CH=N); 9.03 (broad, 1H, NH); 9.31 (broad, 1H, NH); 9.67 (d, J=7.9 Hz, 1H, NH); 9.87 (s, 2H, NH); 12.07 (s, 1H, OH).
- 129 (300 MHz, DMSO- d_6): 0.70 (m; 4H, -CH₂-CH₂-); 3.05 (m, 1H); 3.51 and 4.49 (AB quartet, J=18 Hz, 2H, S-CH₂); 4.38 (s, 3H, O-CH₃); 5.24 (d,

J=4,9 Hz, 1H, β -lactam-H); 5,84 (dd, J=7,9 Hz and 4,9 Hz, 1H, β -lactam-H); 6,86 (s, 1H, thiazolyl-H); 8,19 (d, J=3,9 Hz, 1H); 8,21 (s, 1H, CH=N); 9,72 (d, J=8,0 Hz, 1H, NH); 11,58 (s, 1H).

130 (300 MHz, $\text{CD}_3\text{CN} + \text{D}_2\text{O}$): 1,26 (t, J=7 Hz, 3H); 1,68 (sextet, J=7 Hz, 2H); 1,93 (quintet, J=7 Hz, 2H); 3,93 (t, J=7,1 Hz, 2H); 3,95 (s, 3H, O- CH_3); 3,98 and 4,57 (AB quartet, J=18 Hz, 2H, SCH_2); 5,59 (d, J=4,9 Hz, 1H, β -lactam-H); 6,18 (d, J=4,9 Hz, 1H, β -lactam-H); 7,40 (s, 1H, thiazolyl-H); 8,63 (s, 1H, CH=N).

131 (300 MHz, D_2O): 0,74 (m, 2H); 0,88 (m, 2H); 2,58 and 2,38 (two singulets, 3H, SCH_3); 2,68 (m, 1H); 3,45 and 3,94 (AB-system, broad, 2H, SCH_2); 3,95 (s, 3H, O- CH_3); 5,23 (d, J=4,7 Hz, 1H, β -lactam-H); 5,75 (d, J=4,7 Hz, 1H, β -lactam-H); 7,03 (s, 1H, thiazolyl-H); 8,36 (s, broad, 1H, CH=N).

132 (300 MHz, D_2O): 0,82 (t, J=7,3 Hz, 3H); 1,29 (sextet, J=7 Hz, 2H); 1,56 (quintet, J=7 Hz, 2H); 2,61 and 2,46 (two singulets, 3H, SCH_3); 3,46 (t, J=7,1 Hz, 2H); 3,55 and 4,01 (AB quartet, J=18 Hz, 2H, SCH_2); 3,98 (s, 3H, O- CH_3); 5,25 (d, J=4,9 Hz, 1H, β -lactam-H); 5,78 (d, J=4,9 Hz, 1H, β -lactam-H); 7,05 (s, 1H, thiazolyl-H); 8,39 (s, 1H, CH=N).

133 (300 MHz, $\text{DMSO}-d_6$): 2,68 (m, 2H); 3,73 (m, 2H); 3,57 and 4,23 (AB quartet, J=18 Hz, 2H, SCH_2); 3,96 (s, 3H, O- CH_3); 5,29 (d, J=4,9 Hz, 1H, β -lactam-H); 8,48 (dd, J=8 Hz and J=4,9 Hz, 1H, β -lactam-H); 6,91 (s, 1H, thiazolyl-H); 8,24 (s, 1H, CH=N); 9,20 (s, 1H); 9,90 (d, J=8,0 Hz, 1H NH).

134 (300 MHz, $\text{DMSO}-d_6 + \text{D}_2\text{O}$): 0,68 (m, 2H); 0,84 (m, 2H); 2,91 (m, 1H); 3,62 and 4,22 (AB quartet, J=18 Hz, 2H, SCH_2); 5,28 (d, J=4,9 Hz, 1H, β -lactam-H); 5,85 (d, J=4,8 Hz, 1H, β -lactam-H); 7,06 (s, 1H, thiazolyl-H); 8,23 (s, 1H, CH=N).

- 135 (300 MHz, DMSO- d_6): 0,89 (t, $J=7$ Hz, 3H); 1,29 (sextet, $J=7$ Hz, 2H); 1,54 (quintet, $J=7$ Hz, 2H); 3,51 and 4,47 (AB quartet, $J=18$ Hz, 2H, SCH₂); 3,52 (m, 2H); 5,24 (d, $J=4,8$ Hz, 1H, β -lactam-H); 5,85 (dd, $J=7,9$ Hz and 4,8 Hz, 1H, β -lactam-H); 6,69 (s, 1H, thiazolyl-H); 8,21 (s, 1H, CH=N); 8,47 (m, 1H); 9,55 (d, $J=7,9$ Hz, 1H, NH); 11,44 (s, 1H); 11,54 (s, 1H).
- 136 (300 MHz, DMSO- d_6): 2,77 (s, 3H, NCH₃); 3,0-3,2 (m, 4H); 3,35-3,6 (m, 4H); 3,63 and 4,03 (AB quartet, $J=18$ Hz, 2H, SCH₂); 3,95 (s, 3H, OCH₃); 5,26 (d, $J=4,9$ Hz, 1H, β -lactam-H); 5,84 (dd, $J=7,9$ Hz and $J=4,9$ Hz, 1H, β -lactam-H); 6,85 (s, 1H, thiazolyl-H); 8,40 (s, 1H, CH=N); 9,69 (d, $J=8,0$ Hz, 1H, NH); 11,67 (s, 1H).
- 137 (300 MHz, DMSO- d_6): 3.59 and 4.54 (AB quartet, $J = 18.2$ Hz, 2H, SCH₂); 3.66 (d, $J = 4$ Hz, 3 H, NHCH₃); 3.95 (s, 3 H, O-CH₃); 5.26 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.85 (dd, $J = 5$ Hz and 8 Hz, β -lactam-H); 6.95 (s, 1 H, thiazolyl-H); 7.96 (s, 1 H, CH=N); 8.4 (d, $J = 4$ Hz, NHCH₃); 9.84 (d, $J = 8$ Hz, NH).
- 138 (300 MHz, DMSO- d_6): 1,43 (s, 9H, -OC(CH₃)₃); 3,62 and 4,02 (AB quartet, $J = 17.8$ Hz, 2H, SCH₂); 5,25 (d, $J = 4.9$ Hz, 1H, β -lactam-H); 5,83 (dd, $J = 4.9$ and 8,0 Hz, 1H, β -lactam-H); 6,93 (s, 1H, thiazolyl-H); 8,20 (s, 1H, CH=N); 9,69 (d, $J = 8,0$ Hz, 1H, NH).
- 139 (300 MHz, DMSO- d_6): 3.21 (broad singlet, 4 H); 3.89 (broad singlet, 4 H); 3.50 and 4.53 (AB quartet, $J = 18.1$ Hz, 2H, SCH₂); 5.27 (d, $J = 5$ Hz, 1 H, β -lactam-H); 5.77 (d, $J = 58$ Hz, 2H, -CH₂F); 5.90 (dd, $J = 5$ Hz and 8.2 Hz, β -lactam-H); 8.66 (s, 1 H, CH=N); 9.85 (d, $J = 8.2$ Hz, NH).
- 140 (300 MHz, DMSO- d_6): 1.02 (t, $J=7.4$ Hz, 3H, C-CH₃); 2.32 (qd, $J=7.4$ and 7.5 Hz, 2H, C=C-CH₂-C); 3.52 and 4.15 (AB, $J=17.7$ Hz, 2H, S-CH₂); 5.17 (d, $J=5.2$ Hz, 1H, β -lactam-H); 5.73 (dd, $J=5.2$ and 8.8 Hz,

- 1H, β -lactam-H); 6.48 (s, 1H, CH thiazol); 6.61 (t, J=7.5 Hz, 1H, C=CH-C); 8.93 (s, 1H, CH=N); 9.14 (d, J=8.8 Hz, 1H, NH).
- 141 (90 MHz, DMSO- d_6): 2.3 (s, 3 H, CH₃); 1.8 to 2.1 (m, 1 H); 3.95 (s, 2H, SCH₂); 3.9 (s, 3 H, O-CH₃); 5.35 (d, J = 5 Hz, 1 H, β -lactam-H); 5.9 (dd, J = 5 Hz and 8 Hz, β -lactam-H); 6.95 (s, 1 H, thiazolyl-H); 8.65 (s, 1 H, CH=N); 9.9 (d, J = 8 Hz, NH).
- 142 (90 MHz, DMSO- d_6): 2.3 (s, 3 H, thiazolyl-CH₃); 4.0 (s, 3 H, O-CH₃); 3.75 and 4.3 (AB quartet, J = 18 Hz, 2H, SCH₂); 5.4 (d, J = 5 Hz, 1 H, β -lactam-H); 5.95 (dd, J = 5 Hz and 8 Hz, β -lactam-H); 6.7 (s, 1 H, thiazolyl-H); 7.05 (s, 1 H, thiazolyl-H); 8.55 (s, 1 H, CH=N); 9.95 (d, J = 8 Hz, NH).
- 143 (90 MHz, DMSO- d_6): 2.25 (s, 3 H, thiazolyl-CH₃); 3.60 (s, 3 H, N-CH₃); 3.7 and 4.15 (AB quartet, J = 18 Hz, 2H, SCH₂); 3.95 (s, 3 H, O-CH₃); 5.35 (d, J = 5 Hz, 1 H, β -lactam-H); 5.85 (dd, J = 5 Hz and 8 Hz, β -lactam-H); 6.7 (s, 1 H, thiazolyl-H); 7.02 (s, 1 H, thiazolyl-H); 8.15 (s, 1 H, CH=N); 9.95 (d, J = 8 Hz, NH).
- 144 (300 MHz, DMSO- d_6): 2.83 (d, 3H, NCH₃); 3.55 and 4.23 (AB quartet, J = 19.8 Hz, 2H, SCH₂); 3.84 (s, 3H, =N-OCH₃); 5.21 (d, J = 5.5 Hz, 1H, β -lactam-H); 5.70 (dd, J = 5.5 Hz and 9 Hz, β -lactam-H); 6.77 (s, 1H, thiazolyl-H); 9.28 (s, 1 H, CH=N); 9.63 (d, J = 9 Hz, 1H, NH).
- 145 (300 MHz, DMSO- d_6):
Diastereomer A: 1.25 (d, J = 6 Hz, 3H); 1.24 (d, J = 6 Hz, 3H); 1.53 (d, J = 5.4 Hz, 3H, -O(CH₃)CH-O-); 2.9 (d, J = 4.9 Hz, 3H, NCH₃); 3.62 and 4.61 (AB quartet, J = 18.3 Hz, 2H, SCH₂); 3.94 (s, 3H, =N-OCH₃); 4.75 to 4.84 (m, 1 H, -O-CH(CH₃)₂); 5.34 (d, J = 5 Hz, 1H, β -lactam-H); 5.94 (dd, J = 5 Hz and 7.8 Hz, β -lactam-H); 6.9 (q, J = 5.3 Hz, 1 H, -O(CH₃)CH-O-); 6.92 (s, 1 H, thiazolyl-H); 8.3 (s, 1 H, CH=N); 9.96 (d, J

= 7.8 Hz, 1H, NH).

Diastereomer B: 1.24 (d, J = 6 Hz, 3H); 1.22 (d, J = 6 Hz, 3H); 1.51 (d, J = 5.5 Hz, 3H, -O(CH₃)CH-O-); 2.9 (d, J = 4.9 Hz, 3H, NCH₃); 3.60 and 4.65 (AB quartet, J = 18.3 Hz, 2H, SCH₂); 3.93 (s, 3H, =N-OCH₃); 4.75 to 4.84 (m, 1 H, -O-CH(CH₃)₂); 5.30 (d, J = 5 Hz, 1H, β-lactam-H); 6.04 (dd, J = 5 Hz and 7.6 Hz, β-lactam-H); 6.8 (q, J = 5.3, 1 H, -O(CH₃)CH-O-); 6.92 (s, 1 H, thiazolyl-H); 8.14 (s, 1 H, CH=N); 9.95 (d, J = 7.6 Hz, 1H, NH).

146 (300 MHz, DMSO-d₆):

Diastereomer A: 1.25 (d, J = 6 Hz, 6H); 1.50 (d, J = 5.4 Hz, 3H, -O(CH₃)CH-O-); 2.18 (s, 3H, CH₃CO); 3.76 and 4.48 (AB quartet, J = 17.9 Hz, 2H, SCH₂); 4.7 to 4.9 (m, 1 H, -O-CH(CH₃)₂); 5.31 (d, J = 4.8 Hz, 1H, β-lactam-H); 5.88 (dd, J = 4.8 Hz and 7.6 Hz, β-lactam-H); 6.87 (q, J = 5.3 Hz, 1 H, -O(CH₃)CH-O-); 7.1 (s, 1 H, thiazolyl-H); 8.28 (s, 1 H, CH=N); 9.93 (d, J = 7.6 Hz, 1H, NH).

Diastereomer B: 1.23 (d, J = 6 Hz, 6H); 1.49 (d, J = 5.4 Hz, 3H, -O(CH₃)CH-O-); 2.17 (s, 3H, CH₃CO); 3.70 and 4.38 (AB quartet, J = 18 Hz, 2H, SCH₂); 4.7 to 4.9 (m, 1 H, -O-CH(CH₃)₂); 5.28 (d, J = 4.8 Hz, 1H, β-lactam-H); 5.83 (dd, J = 4.8 Hz and 7.6 Hz, β-lactam-H); 6.80 (q, J = 5.2, 1 H, -O(CH₃)CH-O-); 7.1 (s, 1 H, thiazolyl-H); 8.18 (s, 1 H, CH=O); 9.91 (d, J = 7.6 Hz, 1H, NH).

147 (300 MHz, DMSO-d₆)

Diastereomer A: 1.26 (d, J = 6.2 Hz, 6H); 1.53 (d, J = 5 Hz, 3H, -O(CH₃)CH-O-); 2.29 (s, 6H, 2 aryl-CH₃); 3.60 and 4.54 (AB quartet, J = 18.5 Hz, 2H, SCH₂); 4.75 to 4.84 (m, 1 H, -O-CH(CH₃)₂); 5.34 (d, J = 5 Hz, 1H, β-lactam-H); 5.97 (dd, J = 5 Hz and 7.7 Hz, β-lactam-H); 6.91 (q, J = 5.3 Hz, 1 H, -O(CH₃)CH-O-); 6.92 (s, 1 H, thiazolyl-H); 7.12 and 7.49 (AB quartet, J = 8 Hz, 2 x 4 aromatic-H); 8.34 (s, 1 H, CH=N); 9.69 (d, J = 7.7 Hz, 1H, NH).

Diastereomer B: 1.24 (d, J = 6.2 Hz, 6H); 1.52 (d, J = 5.5 Hz, 3H, -

O(CH₃)CH-O-); 2.29 (3. 6 H, 2 Aryl-CH₃); 3.59 and 4.51 (AB quartet, J = 18.4 Hz, 2H, SCH₂); 4.75 to 4.84 (m, 1 H, -O-CH(CH₃)₂); 5.31 (d, J = 5 Hz, 1H, β-lactam-H); 5.93 (dd, J = 5 Hz and 7.7 Hz, β-lactam-H); 6.83 (q, J = 5.3, 1 H, -O(CH₃)CH-O-); 6.84 (s, 1 H, thiazolyl-H); 7.12 and 7.49 (AB quartet, J = 8 Hz, 2 x 4 aromatic-H); 8.24 (s, 1 H, CH=N); 9.69 (d, J = 7.7 Hz, 1H, NH).

- A) a) (D₂O + DCl): 3.62 (AB quartet, J=16Hz, 2H, S-CH₂); 5.10 (2d, J=5Hz, 2H, β-lactam-H); 6.20 (s, broad, 1H, O-CH-O).
- A) c) (DMSO-d₆): 3.55 and 3.73 (AB quartet, J=18Hz) resp. 3.70 (s), (2H, S-CH₂); 3.87 (s, 3H, N-O-CH₃), 5.11 (d, J=5Hz, β-lactam-H); 5.87 (m, 1H, β-lactam-H); 6.20 resp. 6.26 (s, 1H, O-CH-O); 6.77 resp. 6.78 (s, 1H, thiazolyl-H); 7.27-7.35 (m, 15H, Ar-H); 9.6 (s, broad, 1H, NH-thiazolyl); 9.72 resp. 9.74 (d, J=8Hz, 1H, NH).
- A) d) (DMSO-d₆): 3.58 and 3.76 (AB quartet, J=18Hz) resp. 3.72 (s), (2H, S-CH₂); 3.88 (s, 3H, N-O-CH₃), 5.15 (d, J=5Hz, β-lactam-H); 5.94 (dd, J=8Hz and 5Hz, 1H, β-lactam-H); 6.21 resp. 6.28 (s, 1H, O-CH-O); 6.81 resp. 6.82 (s, 1H, thiazolyl-H); 9.77 resp. 9.78 (d, J=8Hz, 1H, NH).
- B) c) (CDCl₃): 3.2- 3.5 (m, 2H, S-CH₂); 5.05 (d, J=5Hz, β-lactam-H); 6.0 (dd, J= 5 and 8Hz, 1H, β-lactam-H); 6.4 (s, 1H, O-CH-O); 7-7.4 (m, 30H, Ar-H).
- B) d) (DMSO-d₆): 3.72 (m, 2H, S-CH₂); 5.15 (d, J=5Hz, β-lactam-H); 5.95 (dd, J=8Hz and 5Hz, 1H, β-lactam-H); 6.3 (broad s, 1H, O-CH-O); 6.8 (s, 1H, thiazolyl-H); 9.75 (d, J=8Hz, 1H, NH).
- C) (300 MHz, DMSO-d₆): 3.55 and 3.77 (AB quartet, J=18Hz) resp. 3.71 (s), (2H, S-CH₂); 5.14 (d, J=5Hz, β-lactam-H); 5.97 (m, 1H, β-lactam-H); 5.79 (d, J=55 Hz, 2H, -CH₂F); 6.20 resp. 6.27 (s, 1H, O-CH-O); 9.81 resp. 9.84

(d, J=8Hz, 1H, NH).

- D) (300 MHz, DMSO- d_6): 2.20 resp. 2.21 (s, 3H, O=C-CH₃); 3.63 and 3.80 (AB quartet, J=18 Hz) resp. 3.76 (s) (2H, S-CH₂); 5.20 (d, J=5Hz, 1H, β -lactam-H); 6,00 (dd, J=8Hz and 5Hz, 1H, β -lactam-H); 6,23 resp. 6,29 (s, 1H, O-CH-O); 7.16 resp. 7.17 (s, 1H, CH thiazol); 10,04 resp. 10,05 (d, J=8Hz, 1H, NH).
- E) (300 MHz, DMSO- d_6): 3.58 and 3.79 (AB quartet, J=18.2Hz) resp. 3.75 (s) (2H, S-CH₂); 5.17 (d, J=5Hz, 1H, β -lactam-H); 5.94 (dd, J=8Hz and 5Hz, 1H, β -lactam-H); 6,21 resp. 6,28 (s, 1H, O-CH-O); 6.85 resp. 6.86 (s, 1H, CH thiazol); 9.74 (d, J=8Hz, 1H, NH); 12.38 (s, 1H, OH).
- F) c) (300 MHz, DMSO- d_6): 1.4 (2s, 6H, C-(CH₃)₂); 1.5 (s, 9H, C-(CH₃)₃); 3.6 and 3.7 (AB quartet, J=18 Hz) resp. 3.7 (s) (2H, S-CH₂); 5.2 (d, J=5Hz, 1H, β -lactam-H); 5.9 (dd, J=8Hz and 5Hz, 1H, β -lactam-H); 6,2 resp. 6,3 (s, 1H, O-CH-O); 6.8 (s, 1H, CH thiazol); 7.2-7.5 (m, 15H, CH aromatic); 9.6 (d, J=8Hz, 1H, NH).
- F) d) (300 MHz, DMSO- d_6): 1.48 resp. 1.50 (s, 6H, C-(CH₃)₂); 3.60 and 3.77 (AB quartet, J=18 Hz) resp. 3.74 (s) (2H, S-CH₂); 5.19 (d, J=5.2Hz, 1H, β -lactam-H); 6,01 (dd, J=8.5Hz and 5.2Hz, 1H, β -lactam-H); 6,23 resp. 6,29 (s, 1H, O-CH-O); 6.87 resp. 6.88 (s, 1H, CH thiazol); 9.67 (d, J=8.5Hz, 1H, NH).
- G) (300 MHz, DMSO- d_6): 1.00 (t, J=7.5 Hz, 3H, C-CH₃); 1.47 (s, 9H, O-C-(CH₃)₃); 2.27 (qd, J=7.5 Hz, 2H, C=C-CH₂-C); 3.57 and 3.74 (AB quartet, J=18,3 Hz) resp. 3.73 (s) (2H, S-CH₂); 5.11 (d, J=5.1 Hz, 1H, β -lactam-H); 5.88 (dd, J=8.5 Hz and 5.1 Hz, 1H, β -lactam-H); 6,22 resp. 6,26 (s, 1H, O-CH-O); 6.56 (t, J=7.5 Hz, 1H, C=CH-C); 7.05 (s, 1H, CH thiazol); 8.80 resp. 8.81 (d, J=8.4 Hz, 1H, NH).

- H) a) (300 MHz, DMSO- d_6): 2.7 (s, 3H, S-CH₃); 3.5-3.6 (m, 4H, N-CH₂); 3.7-3.8 (m, 2H, N-CH₂); 3.8-3.9 (m, 2H, N-CH₂); 8.1 (s, 1H, CH=O); 9.6 (broad, 2H, NH).
- H) b) (300 MHz, DMSO- d_6): 3.42 (s, 4H, N-CH₂); 3.4-3.6 (m, 4H, N-CH₂); 4.8 (broad, 2H, NH); 7.9 (broad, 2H, NH); 8.1 (s, 1H, CH=O); 9.5 (broad, 1H, NH).
- H) c) (300 MHz, DMSO- d_6): 3.1-3.2 (s, 4H, N-CH₂); 3.7-3.8 (m, 4H, N-CH₂); 4.8 (broad, 2H, NH); 8.0 (broad, 2H, NH); 9.6 (broad, 1H, NH); 10.0 (broad, 2H, NH).
- I) (90 MHz, D₂O): 1,2 ppm (t, 3H); 1,9 - 2,1 ppm (m, 4H); 3,3 - 3,7 ppm (m, 6H).
- J) (90 MHz, DMSO- d_6): 2,9 ppm (d, J = 5 Hz, 3H, NCH₃), 3,4 - 3,8 ppm (m, 8H), 7,55 ppm (broad quartet, 1 H, NH).
- K) (90 MHz, D₂O): 1,3 ppm (s, 9H).
- L) (90 MHz, DMSO- d_6 + D₂O): 2,8 ppm (s, 3H, NCH₃); 3,4 - 3,65 ppm (m, 4H); 4,0 - 4,4 ppm (m, 4H).
- M) (300 MHz, DMSO- d_6): 2.74 (s, 3H, C=N-CH₃); 3.15 (s, 9H, N(CH₃)₃); 3.49 (m broad, 2H, N-CH₂); 3.64 (m broad, 2H, N-CH₂); 4.8 (broad, 2H, NH); 7.8 (broad, 3H, NH).
- N) (90 MHz, DMSO- d_6): 2.85 ppm (s, 3H, NCH₃); 3.2 - 3.65 ppm (m, 8H); 8.1 ppm (s, 1H, CH=O).

- O) (90 MHz, DMSO- d_6 + D₂O): 2,85 ppm (s, 3H, NCH₃); 3,2 - 3,5 ppm (m, 4H); 3,5 - 3,9 ppm (m, 4H).
- P) (300 MHz, D₂O): 2.84 (s, 3H, N-CH₃); 3.3-3.4 (m, 2H, N-CH₂); 3.7-3.8 (m, 2H, N-CH₂).
- Q) a) (90 MHz, DMSO- d_6): 2,65 ppm (s, 3H, S-CH₃); 3,35 ppm (s, 6H, NCH₃)₂; 3,65 - 4,0 ppm (m, 4H); 4,0 - 4,3 ppm (m, 4H), 9,45 ppm (broad singlet, 1H, NH).
- Q) b) (90 MHz, DMSO- d_6): 3,3 ppm (s, 6H, NCH₃)₂; 3,5 - 3,8 ppm (m, 4H); 3,8 - 4,2 ppm (m, 4H).
- R) a) (90 MHz, DMSO- d_6): 2,55 ppm (s, 3H, SCH₃); 3,45 ppm (s, 3H, NCH₃).
- R) b) (90 MHz, DMSO- d_6): 3,15 ppm (s, 3H, NCH₃); 3,2 - 3,28 ppm (m, 2H); 3,28 - 3,35 ppm (m, 2H); 3,4 - 3,55 ppm (m, 4H); 5,18 ppm (broad singlet, 2H); 8,05 (s, 1H, -CH=O); 8,1 - 8,3 (broad singlet, 2H).
- R) c) (300 MHz, DMSO- d_6): 3,16 ppm (m, 3 + 4 H); 3,63 ppm (m, 4H); 6,7 ppm (broad singlet, 5H); 8,5 (broad singlet, 1H); 10,0 ppm (broad singlet, 2H).
- S) (300 MHz, DMSO d_6): 2.55 (s, 2H, N-CH₂); 5.92 (s, 2H, NH).
- T) (300 MHz, DMSO d_6): 0.5 (m, 2H, CH₂); 0.7-0.8 (m, 2H, CH₂); 2.4-2.5 (m, 1H, N-CH); 4.7 (broad, 2H, NH); 7.5 (broad, 2H, NH); 8.2 (broad, 1H, NH); 8.9 (broad, 1H, NH).
- U) (300 MHz, DMSO d_6): 2.7 (s, 3H, N-CH₃); 4.7 (broad, 2H, NH); 7.7


(broad, 1H, NH); 9.2 (broad, 1H, NH/OH); 9.8 (broad, 1H, NH/OH).

- V) (300 MHz, DMSO d_6): 2.79 (d, $J=4.8$ Hz 6H, $N(CH_3)_2$); 3.20 (s, 3H, $N-CH_3$); 3.2 (m, 2H, $N-CH_2$); 3.6 (m, 2H, $N-CH_2$); 4.7 (very broad, 2H, NH); 7.7 (broad, 2H, NH); 10.4 (broad, 1H, NH).
- W) (300 MHz, D_2O): 6.75-6.85 (m, 1H, CH aromatic); 6.9-7.0 (m, 1H, CH aromatic); 7.1-7.15 (m, 1H, CH aromatic); 7.7 (s, 1H, $CH=N$).
- X) (300 MHz, D_2O): 2.0 (m, 1H); 2.47, 2.35 (s, s, together 3H, $-SCH_3$); 0.84 (m, 2H); 0.69 (m, 2H).
- Y) (300 MHz, D_2O): 3.36 (t, $J=7$ Hz, 2H); 2.51, 2.43 (s, s, together 3H, $-SCH_3$); 1.55 (quintet, $J=7$ Hz, 2H); 1.29 (sextet, $J=7$ Hz, 2H); 0.85 (t, $J=7$ Hz, 3H).
- Z) (90 MHz, DMSO- d_6): 3.65 ppm (s, 3H, NCH_3).
- AA) a) (300 MHz, DMSO d_6): 2.19 (s, 3H, $C-CH_3$); 3.84 (s, 3H, $N-CH_3$); 5.84 (d, $J=3.8$ Hz 1H, $C=CH$); 6.58 (d, $J=3.8$ Hz 1H, $C=CH$); 8.76 (s, 1H, NH); 8.93 (s, 1H, NH).
- AA) b) (300 MHz, DMSO d_6): 2.3 (s, 3H, $C-CH_3$); 2.75 (s, 3H, $S-CH_3$); 3.65 (s, 3H, $N-CH_3$); 6.2 (d, $J=4$ Hz 1H, $C=CH$); 7.1 (d, $J=4$ Hz 1H, $C=CH$); 10.6 (s, broad 5H, NH).
- AA) c) (300 MHz, DMSO d_6): 2.2 (s, 3H, $C-CH_3$); 3.1 (s, 3H, $N-CH_3$); 5.95 (d, $J=4$ Hz 1H, $C=CH$); 6.5 (d, $J=4$ Hz 1H, $C=CH$); 7.2 (very broad 5H, NH).
- AB) (300 MHz, DMSO d_6/D_2O): 6.75-6.85 (m, 1H, CH aromatic); 7.00-7.05 (m, 1H, CH aromatic); 7.05-7.10 (m, 1H, CH aromatic).

- AC) (300 MHz, DMSO d_6 /D₂O): 8.24 (s, 1H, CH=N); 5.20 (d, J=5.2 Hz, 1H, β -lactam-H); 4.07 (d, J=5.2 Hz, 1H, β -lactam-H); 3.89 and 3.61 (ABq, J=17.8 Hz, 2H, SCH₂).
- AD) (300 MHz, DMSO d_6 /CD₃CO₂D+CF₃COOD): 8.67 (s, 1H, CH=N); 5.38-5.40 (2d, 2H, 2 β -lactam-H); 4.01 (s, 3H, CH₃-O); 3.98-4.00 (ABq, 2H, SCH₂).
- AE) (300 MHz, DMSO d_6): 8.14 (s, 1H, CH=N); 5.33 (d, J=5.6 Hz, 1H, CH); 4.80 (d, J=5.6 Hz, 1H, CH); 3.88 and 3.58 (ABq, J=17.8 Hz, 2H, SCH₂).
- AF) (300 MHz, DMSO d_6): 7.96 (s, 1H, CH=N); 5.17 (d, J=5.2 Hz, 1H, CH); 5.02 (d, J=5.2 Hz, 1H, CH); 3.96 and 3.47 (ABq, J=17.7 Hz, 2H, SCH₂).
- AG) (300 MHz, DMSO d_6): 8.35 (s, 1H, CH=N); 5.31 (d, J=5.1 Hz, 1H, CH); 5.14 (d, J=5.1 Hz, 1H, CH); 4.28 and 3.84 (ABq, J=17.9 Hz, SCH₂).
- AH) (300 MHz, DMSO d_6): 8.41 (s, 1H, CH=N); 5.34 (d, J=5.1 Hz, 1H, CH); 5.18 (d, J=5.1 Hz, 1H, CH); 4.37 and 3.80 (ABq, J=17.9 Hz, SCH₂).
- AI) (300 MHz, DMSO d_6): 8.61 (s, 1H, CH=N); 5.36 (d, J=5.1 Hz, 1H, CH); 5.18 (d, J=5.1 Hz, 1H, CH); 4.42 und 3.71 (ABq, J=18.0 Hz, SCH₂); 2.74 (s, 3H, SCH₃).
- AJ) (300 MHz, DMSO d_6): 8.52 (s, 1H, CH=N); 5.36 (d, J=5.1 Hz, 1H, CH); 5.21 (d, J=5.1 Hz, 1H, CH); 4.46 and 3.79 (ABq, J=17.7 Hz, 2H, SCH₂); 2.95 (s, 3H, N-CH₃).
- AK) (300 MHz, DMSO d_6): 8.51 (s, 1H, CH=N); 7.56-6.84 (m, 10H, 2Ph); 5.28 (d, J=4.8 Hz, 1H, CH); 5.00 (d, J=5.1 Hz, 1H, CH); 4.13 and 3.93 (ABq, J=16.8 Hz, 2H, SCH₂).

Claims :


1. A compound of formula




wherein

R_1 denotes hydrogen or an ester moiety,

R_2 denotes a group of formula




IIa



IIb

or




IIc

wherein


Y denotes hydrogen, alkyl, alkenyl, acyl, carbamoyl or aryl

R_4 denotes hydrogen, alkyl, alkenyl, cycloalkyl, aryl, acyl or heterocyclyl

R_5 denotes hydrogen, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, or a group of formula




IIId



IIe

or



IIIf

wherein

R_7 denotes alkyl or aryl

R_8 denotes hydrogen, cycloalkyl or alkyl

R_9 denotes hydrogen or alkyl

R_{10} denotes hydrogen, alkyl, hydroxy, amino, phenyl, alkenyl, cycloalkyl, aryl, heterocyclyl or a group of formula



wherein Phe denotes aryl

R_9 and R_{10} together with the nitrogen atom denote heterocyclyl,

Z denotes oxygen, sulphur or $N-R_{13}$, wherein

R_{13} denotes hydrogen, alkyl or cycloalkyl


R_{11} denotes hydrogen, alkyl, aryl, cycloalkyl or heterocyclyl, or

R_4 and R_5 together with the nitrogen atom denote heterocyclyl,


R_6 denotes heterocyclyl, and

Ac denotes


(i) a group



(ii) a group of formula



or



wherein

B denotes N or CH

Z₁ denotes aryl, cycloalkyl, 1,4-cyclohexadienyl or heterocyclyl

Z₂ denotes hydrogen, alkyl or -CH₂COOZ₃, wherein


Z₃ denotes hydrogen, alkyl or cycloalkyl

Z₃ denotes hydrogen or alkyl

Z₄ denotes hydrogen or an organic radical

D denotes oxygen or CH₂.

2. A compound of claim 1 of formula




wherein

W denotes CH or N

V denotes CH or N-O

R₁ denotes hydrogen or an ester moiety,

R₂ denotes a group of formula




wherein


Y denotes hydrogen; unsubstituted lower alkyl; or substituted lower alkyl, by the residue of a carboxylic acid, a carboxylic acid ester or a carboxylic acid amide,

R₄ denotes hydrogen, phenyl, cycloalkyl or lower alkyl

R₅ denotes hydrogen, lower alkyl, heterocyclyl or a group of formulae




IId



IIe

or



IIIf

wherein


R_7 denotes lower alkyl

R_8 denotes hydrogen, cycloalkyl or lower alkyl

R_9 denotes hydrogen or lower alkyl,

R_{10} denotes hydrogen, hydroxy; amino; phenyl; alkenyl; cycloalkyl;

heterocyclyl; unsubstituted alkyl; substituted alkyl, by CF_3 , OH, alkoxy, carboxyl, halogen, amino, monoalkylamino, dialkylamino, trialkylamino, pyridyl or a sulfonic acid residue; a group of formula



wherein

R_{12} denotes hydrogen or lower alkyl,

Z denotes oxygen, sulphur, or N-R_{13} , wherein

R_{13} denotes hydrogen or lower alkyl, and

R_{11} denotes hydrogen; dihydroxyphenyl; cycloalkyl; heterocyclyl;

unsubstituted lower alkyl; substituted lower alkyl by pyridyl or


monoalkylamino, dialkylamino or trialkylamino; and,

R_4 and R_5 and/or R_9 and R_{10} independently of one another together with the nitrogen denote heterocyclyl,

R_6 denotes heterocyclyl, and

R_3 denotes hydrogen; acyl; carboxyl; unsubstituted alkyl; substituted alkyl by halogen or carboxyl.

3. A compound of anyone of claims 1 to 3 of formula



wherein


R₁, is the same as R₁ in formula IA,

V₁ is the same as V in formula IA,

W₁ is the same as W in formula IA

R₃, denotes hydrogen, lower acyl; unsubstituted alkyl; substituted lower alkyl, by carboxyl and/or fluoro; and

R₂, denotes a group of formula




wherein

Y₁ denotes hydrogen; unsubstituted lower alkyl; or substituted alkyl by carboxyl,

R₄, denotes hydrogen or lower alkyl, and

R₅, denotes hydrogen; saturated or unsaturated, unsubstituted heterocyclyl having 5 or 6 ring members and 1 to 3 nitrogen hetero atoms; saturated or unsaturated one or several fold substituted heterocyclyl by oxo, lower alkyl, amino or CF₃, having 5 or 6 ring members and 1 to 3 nitrogen hetero atoms; benzothiazolyl; or a group of formula



wherein

Z_s is the same as Z in formula I,

R_{7s} denotes lower alkyl,

R_{8s} denotes hydrogen, cycloalkyl or lower alkyl,

R_{9s} denotes hydrogen or lower alkyl,


R_{10s} denotes hydrogen; phenyl; allyl; cycloalkyl; unsubstituted alkyl; substituted alkyl by CF_3 , dialkylamino, trialkylamino, hydroxy, pyridyl or SO_3H , and

R_{11s} denotes hydrogen; pyridyl; cycloalkyl; unsubstituted lower alkyl; substituted lower alkyl by pyridyl or trialkylamino; saturated or unsaturated heterocyclyl having 5 or 6 ring members and 1 to 3 nitrogen hetero atoms; or one or several fold substituted heterocyclyl by lower alkyl and/or thiono, having 5 or 6 ring members and 1 to 3 nitrogen hetero atoms;

R_{4s} and R_{5s} together with the nitrogen atom denote heterocyclyl selected from saturated, unsubstituted heterocyclyl having 5 or 6 ring members and 1 or 2 nitrogen hetero atoms; saturated, one or several fold substituted heterocyclyl by oxo or lower alkyl, having 5 or 6 ring members and 1 or 2 nitrogen hetero atoms; and/or

R_{9s} and R_{10s} together with the nitrogen atom denote saturated, unsubstituted heterocyclyl having 5 or 6 ring members and 1 or 2 nitrogen and/or oxygen hetero atoms; unsaturated, one or several fold substituted heterocyclyl by CHO or lower alkyl, having 5 or 6 ring members and 1 or 2 nitrogen and/or oxygen hetero atoms.

4. A compound of any one of claims 1 to 3 of formula



wherein

W denotes CH or N

V denotes CH or N-O

R₁ denotes hydrogen or an ester moiety,

R₂ denotes a group of formula




IIb

wherein

R₄ is as defined in claim 1 and

R₅ denotes a group of formula



wherein

Z denotes N-R₁₃, wherein

R₁₃ is as defined in claim 1, and


R₉ and R₁₀ together with the nitrogen atom denote heterocyclyl which is a piperazinyl.

5. 7-[[[(2-amino-4-thiazolyl)-(Z)-(hydroxyimino)acetyl]amino]-3-[[[(aminoiminomethyl)-hydrazono]methyl]]-3-cephem-4-carboxylic acid;

7-[[[(2-amino-4-thiazolyl)-(Z)-(hydroxyimino)acetyl]-amino]-3-[[[(piperazinoiminomethyl)-hydrazono]methyl]-3-cephem-4-carboxylic acid;

7-[[[(5-Amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluormethoxyimino)acetyl]amino]-3-[[[(piperazinoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid.

6. A compound of formula




wherein

R_{1p} is the same as R_1 in formula I,

Ac is as defined in formula I,

R_{2p} denotes a group of formulae




wherein

Y_p is the same as Y in formula IA,

R_{4p} is the same as R_4 in formula IA, and

R_{5p} denotes hydrogen, cycloalkyl, lower alkyl or a group of formula



wherein

R_{8p} is the same as R_8 in formula IA,

Z_p is the same as Z in formula IA,

R_{9p} is the same as R_9 in formula IA,


R_{7p} denotes methyl,

R_{10p} denotes hydrogen, lower alkyl or hydroxy, and

R_{4p} and R_{5p} and/or R_{9p} and R_{10p} , independently of one another together with the nitrogen denote heterocyclyl, and

a compound of formulae IIbp, IIdp and IIep denote any tautomeric form, in free form, or, where such a form exists, in form of an acid addition salt, inner salt, quaternary salt or hydrate thereof.

7. A compound of formula




wherein

Ac is as defined in formula I

R_{1q} is the same as R_1 in formula IA, and

R_{2q} denotes a group of formulae




wherein

Y_q is the same as Y in formula IA,

R_{4q} is the same as R_4 in formula IA, and

$R_{5,q}$ denotes hydrogen, cycloalkyl, lower alkyl or a group of formulae



IIdq

IIeq

wherein

$R_{7,q}$ is the same as R_7 in formula IA,

$R_{8,q}$ is the same as R_8 in formula IA,

Z_q is the same as Z in formula IA,


$R_{9,q}$ is the same as R_9 in formula IA,

$R_{10,q}$ denotes hydrogen, lower alkyl or hydroxy, and

$R_{4,q}$ and $R_{5,q}$ and/or $R_{9,q}$ and $R_{10,q}$ independently of one another together with the nitrogen denote heterocyclyl, and

a compound of formulae IIbp, IIdp and IIep denote any tautomeric form, in free form, or, where such a form exists, in form of an acid addition salt, inner salt, quaternary salt or hydrate thereof.

8. A process for the production of a compound of formula I as defined in claim I by reaction of a compound of formula



wherein Ac is as defined in formula I and


a) either

- α) R_b denotes hydroxy and R_c and R_d together form a bond, or
 β) R_d denotes hydrogen, a cation, an ester forming group or a silyl group, and
 R_b and R_c together denote oxo,
 in free form or in form of an acid addition salt
 with a group of formula




wherein R_2 is as defined in formula I, or

b) reacting a compound of formula



wherein R_1 and R_2 are as defined in formula I, with a compound of formula



wherein Ac is as defined in formula I and X' denotes a leaving group.

9. A compound of formula



wherein


R_{2i} denotes a group of formula



wherein

R_{4i} is the same as R_4 in formula I,

R_{5i} denotes a group of formula



wherein


Z_i denotes $N-R_{13i}$, wherein

R_{13i} is hydrogen, alkyl or cycloalkyl, and

R_{9i} and R_{10i} together with the nitrogen atom denote heterocyclyl which is a piperazinyl; or

R_{4i} is the same as R_4 in formula I, and

R_{5i} denotes a group of formula



IIdi


wherein

R_{8i} denotes alkyl, preferably at least C_2 alkyl; or cycloalkyl, preferably cyclopropyl, and

R_{7i} denotes alkyl, preferably methyl; and

R_{4i} is the same as R_4 in formula I and

R_{5i} denotes a group of formula



wherein

Z_i denotes $N-R_{13i}$, wherein


R_{13i} denotes hydrogen, alkyl or cycloalkyl

R_{9i} denotes hydrogen and

R_{10i} denotes CH_2CF_3 , $C(CH_3)_3$, OH or an alkyl group having at least 2 carbon atoms which is substituted by dialkyl amine or trialkyl ammonium, hydroxy;
or

R_{4i} is the same as R_4 in formula I,

R_{5i} denotes a group of formula



wherein


Z_i denotes $N-R_{13i}$, wherein

R_{13i} denotes alkyl, and

R_{9i} and R_{10i} together with the nitrogen atom denote heterocyclyl which is morpholyl or pyrrolidinyl; or

R_{4i} is the same as R_4 in formula I and denotes preferably hydrogen

R_{5i} denotes a group of formula



wherein

Z_i denotes $N-R_{13i}$, wherein


R_{13i} denotes hydrogen, alkyl or cycloalkyl,

R_{9i} denotes hydrogen, and

R_{10i} denotes cycloalkyl; or

R_{4i} is the same as R_4 in formula I,

R_{5i} denotes a group of formula



wherein

Z_i denotes $N-R_{13i}$, wherein

R_{13i} denotes hydrogen, alkyl or cycloalkyl,

R_{9i} denotes hydrogen or alkyl, and


R_{10i} denotes a group



wherein Phe denotes phenyl or

R_{4i} is the same as R_4 in formula I,

R_{5i} denotes a group of formula



wherein


Z_i denotes $N-R_{13i}$, wherein

R_{13i} denotes hydrogen, alkyl or cycloalkyl,


R_{III} denotes a dihydroxyphenyl or substituted pyrrolyl by alkyl; or

Z_i denotes oxygen and

R_{III} denotes the group of formula



10. A compound according to claim 8 of formula






wherein

R_x is a group of formula





or








or

 R_y is NH and R_z is hydrogen; or R_x is a group of formula


or




or

 R_y is NH and R_z is CH_3 ; or R_x is $-\text{SCH}_3$ R_y is a group of formula


or



and

 R_z is hydrogen; or R_x is a group of formula


or



or




or



R_y is N - CH₃ and

R_z is hydrogen; or


R_x is the group



R_y is N - C₂H₅ and

R_z is hydrogen; or


R_x is the group



R_y is oxygen and

R_z is hydrogen.


11. A compound of formula



wherein

R_1 is as defined in formula I and

R_{xx} denotes a group



wherein

R_x , R_y and R_z as defined in claim 9.

12. A compound of formulae I, IA, I_p, I_q, IVi, IVa or VIa according to any preceding claim in free form.
13. A compound of formulae I, IA, I_p, I_q, IVi, IVa or VIa according to any preceding claim in salt form.
14. A compound of formulae I, IA, I_p, I_q, IVi, IVa or VIa according to claim 13 in acid addition salt form.
15. A compound of formulae I, IA, I_p, I_q, IVi, IVa or VIa according to claim 13 in metal salt form.
16. A compound of formulae I, IA, I_p, I_q, IVi, IVa or VIa according to any one of claims 12 to 15 in solvate form.
17. Pharmaceutical composition, comprising a compound of claim 1 in pharmaceutically acceptable salt form or free form in association with at least one pharmaceutical carrier or diluent.
18. A compound of claim 1, or a composition of claim 17, for use as a pharmaceutical.
19. A compound of claim 1, or a composition of claim 17, for use as an as an antibioticum.

20. A compound of claim 1 for use in the preparation of a medicament for the treatment of microbial diseases.
21. A compound of claim 1 for use according to claim 20 in the treatment of microbial diseases caused by bacterias selected from *Pseudomonas*, *Enterobacter*, *Enterococcus*, *Moraxella*, *Haemophilus*, *Klebsiella*, *Streptococcus*, *Staphylococcus*, *Escherichia*, or *Proteus*.
22. Use of a compound of formula I as defined in claim 1, or use of a composition as defined in claim 11, as a pharmaceutical.
23. A method of treatment of microbial diseases which comprises administering to a subject in need of such treatment an effective amount of a compound of formula I.

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/EP 96/02023

 A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07D501/24 A61K31/545

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	FR,A,2 191 881 (CIBA-GEIGY AG) 8 February 1974 see page 82 - page 89; claims ---	1-22
A	FR,A,2 220 248 (SHIONOGI & CO LTD) 4 October 1974 see page 32 - page 37; claims ---	1-22
A	FR,A,2 248 845 (SHIONOGI & CO,LTD) 23 May 1975 see page 34 - page 41; claims ---	1-22
A	DE,A,22 62 500 (ELI LILLYAND CO) 5 July 1973 see page 44 - page 51; claims ---	1-22
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

Date of the actual completion of the international search

29 August 1996

Date of mailing of the international search report

05.09.96

Name and mailing address of the ISA

 European Patent Office, P.B. 3818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+ 31-70) 340-3016

Authorized officer

Luyten, H

INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/EP 96/02023

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 88, no. 17, 24 April 1978 Columbus, Ohio, US; abstract no. 121203u, page 551; column 1; XP002011061 see abstract & JP,A,07 783 865 (TAKEDA CHEMICAL INDUSTRIES LTD)	1-22
A	--- CHEMICAL ABSTRACTS, vol. 92, no. 9, 3 March 1980 Columbus, Ohio, US; abstract no. 76491f, page 679; column r; XP002011062 see abstract & JP,A,07 970 294 (TAKEDA CHEMICAL INDUSTRIES LTD)	1-22
A	--- CHEMICAL ABSTRACTS, vol. 85, no. 7, 16 August 1976 Columbus, Ohio, US; abstract no. 46704r, page 543; column r; XP002011063 see abstract & JP,A,75 131 982 (SHIONOGI AND CO.,LTD)	1-22
A	--- CHEMICAL ABSTRACTS, vol. 84, no. 11, 15 March 1976 Columbus, Ohio, US; abstract no. 74282z, page 455; column r; XP002011064 see abstract & JP,A,07 593 990 (TAKEDA CHEMICAL INDUSTRIES, LTD)	1-22
A	--- CHEMICAL ABSTRACTS, vol. 84, no. 7, 16 February 1976 Columbus, Ohio, US; abstract no. 44095y, page 500; column r; XP002011065 see abstract & JP,A,07 583 391 (SHIONOGI AND CO.,LTD)	1-22
	--- -/--	

INTERNATIONAL SEARCH REPORT

International Application No. 7
PCT/EP 96/02023

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 84, no. 5, 2 February 1976 Columbus, Ohio, US; abstract no. 31096z, page 470; column 1; XP002011066 see abstract & JP,A,07 576 085 (SHIONOGI AND CO., LTD) ---	1-22
A	CHEMICAL ABSTRACTS, vol. 83, no. 1, 7 July 1975 Columbus, Ohio, US; abstract no. 10104q, page 850; column r; XP002011067 see abstract & JP,A,74 124 091 (TAKEDA CHEMICAL INDUSTRIES LTD.) ---	1-22
A	CHEMICAL ABSTRACTS, vol. 83, no. 25, 22 December 1975 Columbus, Ohio, US; abstract no. 206299b, page 399; column 1; XP002011068 see abstract & JP,A,07 513 389 (TAKEDA CHEMICAL INDUSTRIES, LTD) -----	1-22

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 96/02023

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 23 is directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat'l Application No

PCT/EP 96/02023

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A-2191881	08-02-74	BE-A- 802020 DE-A- 2333263 NL-A- 7309511	07-01-74 24-01-74 09-01-74
FR-A-2220248	04-10-74	JP-A- 49109391 AU-B- 6609174 CH-A- 601311 DE-A- 2409647 GB-A- 1466954 NL-A- 7402776 US-A- 3987039 US-A- 4053469	17-10-74 28-08-75 14-07-78 12-09-74 16-03-77 30-08-74 19-10-76 11-10-77
FR-A-2248845	23-05-75	JP-A- 50093989 CH-A- 608809 DE-A- 2450618 GB-A- 1460377	26-07-75 31-01-79 30-04-75 06-01-77
DE-A-2262500	05-07-73	NONE	